School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Nabil Saba MD/FACP

  • Department of Hematology and Medical Oncology
    Professor
  • (404) 778-1900
  • nfsaba@emory.edu
Head shot of Nabil Saba

Overview

Nabil Saba, MD, FACP, is a recognized expert on immunotherapy and various systemic therapy modalities for head and neck cancer. His work is focused on translational research and the study and development of novel therapeutic agents in head and neck and esophageal cancer. He leads several clinical trials and chairs national as well as investigator initiated multi-institution studies focusing on novel approaches for treating these diseases.

Dr. Saba is the elected Chair of the National Cancer Institute's task force for recurrent metastatic head and neck cancer, and chaired the Rare Tumors Task Force of the National Cancer Institute's Head and Neck Cancer Steering Committee; he was recognized by the NCI for his outstanding service as committee chair. Prior to joining the faculty at Emory University, he was recognized for his outstanding contribution to the fellowship program at the University of Minnesota. Dr. Saba is also an active member of the NRG Oncology and Eastern Cooperative Oncology Group (ECOG) Head and Neck Cancer Core Committees and has served on the American College of Radiology appropriateness criteria panel for head and neck cancer. In addition, Dr Saba has been appointed as a member of the ASCO clinical guidelines committee as well as the ASCO Head and Neck Guideline Advisory Group.

Dr. Saba's research is focused on clinical and translational work in head and neck, and esophageal cancer. He has been the recipient of several NIH and industry funded grant support to study these malignancies. He is the recipient of funding from the NIH to examine novel genomic approaches for diagnosing HPV positive oropharyngeal cancers. He conducts and leads a large number of head and neck cancer clinical trials with a focus on biomarker endpoints.

Among Dr Saba's contributions is serving as a co-leader of project 4 of the previous Emory Head and Neck Cancer SPORE involving the application of nano-therapeutics-based therapy for treating advanced head and neck cancer and serving as a principal investigator of the recently submitted Emory Head and Neck Cancer SPORE Grant.

Dr. Saba has authored more than 150 multiple peer-reviewed articles, editorials, review papers, book chapters as well as two Uptodate chapters. He is editor of the textbook, "Esophageal Cancer; Prevention, Diagnosis and Treatment." He is associate editor for Head Neck and a member of the editorial board of Cancer, Oral Oncology, American Journal of Clinical Oncology and Cancers of the Head and Neck. He has been recognized as an outstanding reviewer for the journal, Cancer.

Academic Appointment

  • Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

  • MD from American University of Beirut, Medical School
  • BS from American University of Beirut
  • French Baccalaureate from Georgia

Research

Focus

  • I focus on clinical and translational research for aero-digestive malignancies, specifically head and neck, esophageal, and lung cancer. I lead trials for HNC and I co-lead project 4 of the SPORE. My goal is to continue collaborations with basic scientists to advance drug development and clinical trials for aero-digestive tumors.

Publications

  • Radiotherapy With Cisplatin vs Carboplatin Paclitaxel for Head and Neck Squamous Cell Carcinoma.
    JAMA Otolaryngol Head Neck Surg
    06/26/2025 Authors: Abousaud M; Pamulapati S; Rashid S; Lozano F; Shepherd M; Fowowe B; Cao Y; Kim P; Liu Y; Bates JE
  • Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163.
    Clin Cancer Res Volume: 31 Page(s): 2339 - 2346
    06/13/2025 Authors: Saba NF; Flamand Y; Lin DT; Chung CH; McDonald MW; Flampouri S; Khan SA; Snyderman CH; Hanna EY; El-Sayed IH
  • Blocking the TCA Cycle in Cancer Cells Potentiates CD36+ T-cell-Mediated Antitumor Immunity by Suppressing ER Stress-Associated THBS2 Signaling.
    Cancer Res Volume: 85 Page(s): 2014 - 2026
    06/02/2025 Authors: Yang J; Chen F; Fu Z; Yang F; Saba NF; Teng Y
  • Treatment of recurrent oral carcinoma cuniculatum with immune checkpoint blockade: A case report and literature review.
    Oral Oncol Rep Volume: 14
    06/01/2025 Authors: Jones W; Kaka AS; Rudra S; Lubin D; Saeed F; Magliocca KR; Saba NF; Schmitt NC
  • Ushering in Neoadjuvant Immune Checkpoint Inhibitors for Mucosal Head and Neck Squamous Cell Carcinoma.
    JAMA Otolaryngol Head Neck Surg Volume: 151 Page(s): 625 - 626
    06/01/2025 Authors: Windon MJ; Saba NF; Amit M
  • The Limitations of Artificial Intelligence in Head and Neck Oncology.
    Adv Ther Volume: 42 Page(s): 2559 - 2568
    06/01/2025 Authors: Rao KN; Fernandez-Alvarez V; Guntinas-Lichius O; Sreeram MP; de Bree R; Kowalski LP; Forastiere A; Pace-Asciak P; Rodrigo JP; Saba NF
  • Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.
    J Clin Oncol Page(s): JCO2500759
    05/31/2025 Authors: Zandberg DP; Allred JB; Rosenberg AJ; Kaczmar JM; Swiecicki P; Julian RA; Poklepovic AS; Bauman JR; Phan MD; Saba NF
  • Feasibility Assessment of Autologous Human Immune System (HIS) ImmunoGraft Platform Development Using Autologous Mobilized Peripheral Blood (MPB) CD34 Cells Derived from Adult HNSCC Patient.
    Int J Mol Sci Volume: 26
    05/30/2025 Authors: Verma B; Chen GZ; Waller EK; Patel M; Anderson A; Goodwin N; Wesa A; Teng Y; Saba NF
  • When Neck Dissection is Not Indicated in the Treatment of the Clinically Node-Negative Head and Neck Squamous Cell Carcinoma.
    Oncol Ther
    05/23/2025 Authors: Hamoir M; de Bree R; Strojan P; Saba NF; Ferlito A
  • Inhibiting FAT1 Blocks Metabolic Bypass to Enhance Antitumor Efficacy of TCA Cycle Inhibition through Suppressing CPT1A-Dependent Fatty Acid Oxidation.
    Adv Sci (Weinh) Page(s): e02146
    05/23/2025 Authors: Chen F; Yang J; Popoola DO; Yang F; Liu Y; Wang D; Qin ZS; Chen Z; Saba NF; Chen ZG
  • Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.
    JAMA Volume: 333 Page(s): 1599 - 1607
    05/13/2025 Authors: Haddad R; Fayette J; Teixeira M; Prabhash K; Mesia R; Kawecki A; Dechaphunkul A; Dinis J; Guo Y; Masuda M
  • Artificial intelligence-based virtual staining platform for identifying tumor-associated macrophages from hematoxylin and eosin-stained images.
    Eur J Cancer Volume: 220 Page(s): 115390
    05/02/2025 Authors: Aggarwal A; Jana M; Singh A; Dam T; Maurya H; Pathak T; Orsulic S; Yang K; Chute D; Bishop JA
  • Deep Learning Model of Primary Tumor and Metastatic Cervical Lymph Nodes From CT for Outcome Predictions in Oropharyngeal Cancer.
    JAMA Netw Open Volume: 8 Page(s): e258094
    05/01/2025 Authors: Song B; Leroy A; Yang K; Khalighi S; Pandav K; Dam T; Lee J; Stock S; Li XT; Sonuga J
  • STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.
    Future Oncol Volume: 21 Page(s): 1349 - 1356
    05/01/2025 Authors: Saba NF; Harrington K; Licitra L; Machiels J-P; He C; Jew T; Andrianov V; Haddad R
  • Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up.
    Head Neck
    04/28/2025 Authors: Kim P; Saba NF; McCook-Veal A; Liu Y; Klein AM; Beitler JJ; Chen A; Khuri FR; Shin DM
  • Older Patients with Head and Neck Cancer: A Scoping Review of Differences Regarding Diagnosis and Outcomes.
    Head Neck
    04/25/2025 Authors: Arajo ALD; Kowalski LP; Sanabria A; Santos-Silva AR; Coca-Pelaz A; Robbins KT; Rodrigo JP; Guntinas-Lichius O; Lpez F; Mkitie AA
  • Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.
    J Clin Oncol Volume: 43 Page(s): 1369 - 1392
    04/10/2025 Authors: Holsinger FC; Ismaila N; Adkins DR; Barber BR; Burnette G; Fakhry C; Galloway TJ; Goepfert RP; Miles BA; Paleri V
  • Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.
    J Pain Symptom Manage Volume: 69 Page(s): 370 - 384
    04/01/2025 Authors: Price SN; Lee J-W; Gareen IF; Kircher SM; Kumar SK; Mayer IA; Saba NF; Fenske TS; Atkins MB; Hodi FS
  • Deep learning informed multimodal fusion of radiology and pathology to predict outcomes in HPV-associated oropharyngeal squamous cell carcinoma.
    EBioMedicine Volume: 114 Page(s): 105663
    04/01/2025 Authors: Song B; Leroy A; Yang K; Dam T; Wang X; Maurya H; Pathak T; Lee J; Stock S; Li XT
  • Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Cancer Immunol Immunother Volume: 74 Page(s): 142
    03/08/2025 Authors: Wang X; Li T; Slebos RJC; Chaudhary R; Guevara-Patino JA; Bonomi M; Saba NF; Chung CH
  • Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer.
    Cancer Med Volume: 14 Page(s): e70718
    03/01/2025 Authors: Kristoff TJ; Evans S; Nayi P; Abousaud M; Goyal S; Liu Y; Shin D; Steuer CE; Saba NF; Schmitt NC
  • The widespread application of trans-oral robotic surgery in HPV-related head and neck cancer: one size does not fit all.
    J Natl Cancer Inst Volume: 117 Page(s): 388 - 390
    03/01/2025 Authors: Patel MR; Burtness B; Ferris RL; Saba NF
  • DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.
    Nat Commun Volume: 16 Page(s): 1518
    02/12/2025 Authors: Morrow MP; Gillespie E; Sylvester A; Amin MR; Belafsky PC; Best SR; Friedman AD; Klein AM; Lott DG; Mau T
  • Tumor secretome shapes the immune landscape during cancer progression.
    J Exp Clin Cancer Res Volume: 44 Page(s): 47
    02/10/2025 Authors: Yang J; Tang S; Saba NF; Shay C; Teng Y
  • The potential of real-time dynamic disease monitoring with circulating tumor DNA: important lessons from Epstein-Barr virus-related nasopharyngeal carcinoma.
    Lancet Reg Health West Pac Volume: 55 Page(s): 101475
    02/01/2025 Authors: Saba NF; Ma BBY
  • Post COVID-19 and Long COVID Symptoms in Otorhinolaryngology-A Narrative Review.
    J Clin Med Volume: 14
    01/14/2025 Authors: Guntinas-Lichius O; Bitter T; Takes R; Lee VHF; Saba NF; Mkitie AA; Kowalski LP; Nixon IJ; Ferlito A
  • SMAC-armed oncolytic virotherapy enhances the anticancer activity of PD1 blockade by modulating PANoptosis.
    Biomark Res Volume: 13 Page(s): 8
    01/09/2025 Authors: Chen F; Lang L; Yang J; Yang F; Tang S; Fu Z; Saba NF; Luo M; Teng Y
  • Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single-institution experience of clinicopathologic correlation with cytologic findings.
    Cancer Cytopathol Volume: 133 Page(s): e22905
    01/01/2025 Authors: Hsiao W-Y; Saba NF; Lubin D; Chen A; Shi Q
  • DNA methylation profiles of cancer-related fatigue associated with markers of inflammation and immunometabolism.
    Mol Psychiatry Volume: 30 Page(s): 76 - 83
    01/01/2025 Authors: Xiao C; Peng G; Conneely KN; Zhao H; Felger JC; Wommack EC; Higgins KA; Shin DM; Saba NF; Bruner DW
  • Leveraging Saliva for Insights into Head and Neck Cancer.
    Int J Mol Sci Volume: 25
    12/17/2024 Authors: Rashid S; Puttagunta P; Pamulapati S; Yang J; Pocha S; Saba NF; Teng Y
  • A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis.
    Laryngoscope Volume: 134 Page(s): 5041 - 5046
    12/01/2024 Authors: Best SR; Bock JM; Fowler NB; Raabe EH; Klein AM; Laetsch TW; McClellan K; Rinkel RNPM; Saba NF; Sidell DR
  • Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.
    Cancers (Basel) Volume: 16
    11/24/2024 Authors: Xue E; Bracken-Clarke D; Krause H; Adeyelu T; Evans MG; Akbulut D; Quezado M; Gandhi N; Farrell A; Soares HP
  • Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
    Clin Cancer Res Volume: 30 Page(s): 4601 - 4608
    10/15/2024 Authors: Saba NF; Chaudhary R; Kirtane K; Marra A; Ekpenyong A; McCook-Veal A; Schmitt NC; Gross JH; Patel MR; Remick J
  • Therapeutic Targeting of the GLS1-c-Myc Positive Feedback Loop Suppresses Glutaminolysis and Inhibits Progression of Head and Neck Cancer.
    Cancer Res Volume: 84 Page(s): 3223 - 3234
    10/01/2024 Authors: Yang J; Chen F; Lang L; Yang F; Fu Z; Martinez J; Cho A; Saba NF; Teng Y
  • Psychological Factors Related to Treatment Outcomes in Head and Neck Cancer.
    Adv Ther Volume: 41 Page(s): 3489 - 3519
    09/01/2024 Authors: Mkitie AA; Alabi RO; Pulkki-Rback L; Almangush A; Beitler JJ; Saba NF; Strojan P; Takes R; Guntinas-Lichius O; Ferlito A
  • Assessing survival outcomes of patients with oral tongue squamous cell carcinoma: Focus on age, sex, and stage.
    Head Neck Volume: 46 Page(s): 2167 - 2177
    09/01/2024 Authors: Pamulapati S; Abousaud M; Li Y; Ekpenyong A; Rudra S; Remick JS; Bates JE; Stokes WA; McDonald MW; Schmitt NC
  • Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
    Nat Med Volume: 30 Page(s): 2373
    08/01/2024 Authors: Saba NF; Steuer CE; Ekpenyong A; McCook-Veal A; Magliocca K; Patel M; Schmitt NC; Stokes W; Bates JE; Rudra S
  • Exploring the impact of GSTM1 as a novel molecular determinant of survival in head and neck cancer patients of African descent.
    J Exp Clin Cancer Res Volume: 43 Page(s): 203
    07/23/2024 Authors: Yang F; Chen F; Shay C; Chen GZ; Saba NF; Teng Y
  • ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.
    Diagn Cytopathol Volume: 52 Page(s): 353 - 361
    07/01/2024 Authors: Sirotnikov S; Griffith CC; Lubin D; Zhang C; Saba NF; Li D; Kornfield A; Chen A; Shi Q
  • Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial.
    JAMA Oncol Volume: 10 Page(s): 896 - 904
    07/01/2024 Authors: Saba NF; Wong SJ; Nasti T; McCook-Veal AA; McDonald MW; Stokes WA; Anderson AM; Ekpenyong A; Rupji M; Abousaud M
  • Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success.
    Lancet Volume: 403 Page(s): 2667 - 2669
    06/22/2024 Authors: Saba NF
  • Stereotactic Body Radiotherapy as a Curative Treatment for De Novo Mucosal Carcinoma of the Head and Neck: A Feasible Alternative Option for Fragile Patients with Small Lesion: A Systematic Review.
    Cancers (Basel) Volume: 16
    05/31/2024 Authors: Strojan P; Kokalj M; Plavc G; Ng SP; Nuyts S; Chiesa-Estomba CM; Eisbruch A; de Bree R; Chow JCH; Mkitie AA
  • Initial surgical management of sporadic medullary thyroid cancer: Guidelines based optimal care - A systematic review.
    Clin Endocrinol (Oxf) Volume: 100 Page(s): 468 - 476
    05/01/2024 Authors: Cohen O; Tzelnick S; Randolph G; Rinaldo A; lvarez F; Rodrigo JP; Saba NF; Nuyts S; Corry J; Mkitie AA
  • Poorly differentiated thyroid carcinomas: conceptual controversy and clinical impact.
    Virchows Arch Volume: 484 Page(s): 733 - 742
    05/01/2024 Authors: Coca-Pelaz A; Rodrigo JP; Agaimy A; Williams MD; Saba NF; Nuyts S; Randolph GW; Lpez F; Vander Poorten V; Kowalski LP
  • Update on olfactory neuroblastoma.
    Virchows Arch Volume: 484 Page(s): 567 - 585
    04/01/2024 Authors: Lopez F; Agaimy A; Franchi A; Surez C; Vander Poorten V; Mkitie AA; Homma A; Eisbruch A; Olsen KD; Saba NF
  • Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer.
    J Exp Clin Cancer Res Volume: 43 Page(s): 76
    03/12/2024 Authors: Yang F; Yuan C; Chen F; Qin ZS; Schmitt NC; Lesinski GB; Saba NF; Teng Y
  • HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.
    Sci Adv Volume: 10 Page(s): eadk3663
    02/23/2024 Authors: Chen F; Tang C; Yang F; Ekpenyong A; Qin R; Xie J; Momen-Heravi F; Saba NF; Teng Y
  • The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group trials.
    Cancer Volume: 130 Page(s): 439 - 452
    02/01/2024 Authors: Walter AW; Lee J-W; Streck JM; Gareen IF; Herman BA; Kircher SM; Carlos RC; Kumar SK; Mayer IA; Saba NF
  • Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.
    Laryngoscope Volume: 134 Page(s): 577 - 581
    02/01/2024 Authors: So RJ; Hidalgo Lopez JC; Ballestas SA; Klein AM; Steuer C; Shin DM; Abousaud M; Teng Y; Saba NF; Tkaczuk AT
  • Cancer metabolism and carcinogenesis.
    Exp Hematol Oncol Volume: 13 Page(s): 10
    01/29/2024 Authors: Yang J; Shay C; Saba NF; Teng Y
  • Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53.
    Cancer Immunol Immunother Volume: 73 Page(s): 10
    01/17/2024 Authors: Kinney BLC; Gunti S; Kansal V; Parrish CJ; Saba NF; Teng Y; Henry MK; Su F-Y; Kwong GA; Schmitt NC
  • CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.
    Oncoimmunology Volume: 13 Page(s): 2367777
    01/01/2024 Authors: Kinney BLC; Brammer B; Kansal V; Parrish CJ; Kissick HT; Liu Y; Saba NF; Buchwald ZS; El-Deiry MW; Patel MR
  • Correction: Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
    PLoS One Volume: 19 Page(s): e0308819
    01/01/2024 Authors: Saba NF; Dinasarapu AR; Magliocca KR; Dwivedi B; Seby S; Qin ZS; Patel M; Griffith CC; Wang X; El-Deiry M
  • Associations of differentially expressed genes with psychoneurological symptoms in patients with head and neck cancer: A longitudinal study.
    J Psychosom Res Volume: 175 Page(s): 111518
    12/01/2023 Authors: Lin Y; Peng G; Bruner DW; Miller AH; Saba NF; Higgins KA; Shin DM; Claussen H; Johnston HR; Houser MC
  • A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Target Oncol Volume: 18 Page(s): 853 - 868
    11/01/2023 Authors: Razak ARA; Wang H-M; Chang J-Y; Ahn M-J; Munster P; Blumenschein G; Solomon B; Lim DW-T; Hong R-L; Pfister D
  • Progress and emerging strategies to preserve function in the treatment of sinonasal cancer.
    Head Neck Volume: 45 Page(s): 2955 - 2966
    11/01/2023 Authors: Robbins KT; Ronen O; Saba NF; Strojan P; Vander Poorten V; Mkitie A; Lpez F; Rodrigo JP; Homma A; Hanna E
  • Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials.
    Cancer Epidemiol Biomarkers Prev Volume: 32 Page(s): 1552 - 1557
    11/01/2023 Authors: Streck JM; Lee J-W; Walter AW; Rosen RL; Gareen IF; Kircher SM; Herman BA; Carlos RC; Kumar S; Mayer IA
  • Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis.
    Laryngoscope Volume: 133 Page(s): 3087 - 3093
    11/01/2023 Authors: Mau T; Amin MR; Belafsky PC; Best SR; Friedman AD; Klein AM; Lott DG; Paniello RC; Pransky SM; Saba NF
  • Iron, Ferroptosis, and Head and Neck Cancer.
    Int J Mol Sci Volume: 24
    10/12/2023 Authors: Teng Y; Gao L; Mkitie AA; Florek E; Czarnywojtek A; Saba NF; Ferlito A
  • Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis.
    Laryngoscope Volume: 133 Page(s): 2725 - 2733
    10/01/2023 Authors: Ballestas SA; Hidalgo Lopez J; Klein AM; Steuer C; Shin DM; Abousaud M; Schmitt NC; Teng Y; Saba NF; Tkaczuk AT
  • Circulating short chain fatty acids and fatigue in patients with head and neck cancer: A longitudinal prospective study.
    Brain Behav Immun Volume: 113 Page(s): 432 - 443
    10/01/2023 Authors: Xiao C; Fedirko V; Claussen H; Richard Johnston H; Peng G; Paul S; Maner-Smith KM; Higgins KA; Shin DM; Saba NF
  • Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck.
    Cancers (Basel) Volume: 15
    09/23/2023 Authors: Hartl DM; Guerlain J; Gorphe P; Kapre M; Kapre Gupta N; Saba NF; Robbins KT; Ronen O; Rodrigo JP; Strojan P
  • Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol Volume: 41 Page(s): 3851 - 3862
    08/01/2023 Authors: Bauman JE; Saba NF; Roe D; Bauman JR; Kaczmar J; Bhatia A; Muzaffar J; Julian R; Wang S; Bearelly S
  • Artificial Intelligence in Head and Neck Cancer: A Systematic Review of Systematic Reviews.
    Adv Ther Volume: 40 Page(s): 3360 - 3380
    08/01/2023 Authors: Mkitie AA; Alabi RO; Ng SP; Takes RP; Robbins KT; Ronen O; Shaha AR; Bradley PJ; Saba NF; Nuyts S
  • Longitudinal associations among physical activity, inflammatory markers, and quality of life in patients with head and neck cancer.
    Head Neck Volume: 45 Page(s): 1952 - 1966
    08/01/2023 Authors: Huang S; Zhan Y; Jeon S; Bruner DW; Miller AH; Felger JC; Wommack EC; Saba NF; Higgins KA; Irwin ML
  • Survival Outcomes in T3 Laryngeal Cancers: Primary Total Laryngectomy vs. Concurrent Chemoradiation or Radiation Therapy-A Meta-Analysis.
    Biomedicines Volume: 11
    07/28/2023 Authors: Rao KN; Pai PS; Dange P; Kowalski LP; Strojan P; Mkitie AA; Guntinas-Lichius O; Robbins KT; Rodrigo JP; Eisbruch A
  • The expanding role of IAP antagonists for the treatment of head and neck cancer.
    Cancer Med Volume: 12 Page(s): 13958 - 13965
    07/01/2023 Authors: Kansal V; Kinney BLC; Uppada S; Saba NF; Stokes WA; Buchwald ZS; Schmitt NC
  • Associations of inflammation with neuropsychological symptom cluster in patients with Head and neck cancer: A longitudinal study.
    Brain Behav Immun Health Volume: 30 Page(s): 100649
    07/01/2023 Authors: Amirkhanzadeh Barandouzi Z; Bruner DW; Miller AH; Paul S; Felger JC; Wommack EC; Higgins KA; Shin DM; Saba NF; Xiao C
  • Patient-reported outcomes in immunotherapy for head and neck cancer.
    Head Neck Volume: 45 Page(s): 1761 - 1771
    07/01/2023 Authors: Kirtane K; Hoogland AI; Li X; Rodriguez Y; Scheel K; Small BJ; Oswald LB; Muzaffar J; Kish JA; Bonomi M
  • Unsupervised Hierarchical Clustering of Head and Neck Cancer Patients by Pre-Treatment Plasma Metabolomics Creates Prognostic Metabolic Subtypes.
    Cancers (Basel) Volume: 15
    06/14/2023 Authors: Eldridge RC; Qin ZS; Saba NF; Houser MC; Hayes DN; Miller AH; Bruner DW; Jones DP; Xiao C
  • Insurance Authorization and Access to Proton Therapy for Patients With Head and Neck Cancers.
    Int J Radiat Oncol Biol Phys Volume: 116 Page(s): 404 - 412
    06/01/2023 Authors: McDonald MW; Bates JE; McCall NS; Goyal S; Liu Y; Rudra S; Remick JS; Tian S; El-Deiry MW; Saba NF
  • Recurrent Differentiated Thyroid Cancer: The Current Treatment Options.
    Cancers (Basel) Volume: 15
    05/10/2023 Authors: Coca-Pelaz A; Rodrigo JP; Shah JP; Nixon IJ; Hartl DM; Robbins KT; Kowalski LP; Mkitie AA; Hamoir M; Lpez F
  • Management of Older Patients with Head and Neck Cancer: A Comprehensive Review.
    Adv Ther Volume: 40 Page(s): 1957 - 1974
    05/01/2023 Authors: Matos LL; Sanabria A; Robbins KT; Halmos GB; Strojan P; Ng WT; Takes RP; Angelos P; Piazza C; de Bree R
  • Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
    J Clin Oncol Volume: 41 Page(s): 2166 - 2180
    04/20/2023 Authors: Haddad RI; Harrington K; Tahara M; Ferris RL; Gillison M; Fayette J; Daste A; Koralewski P; Zurawski B; Taberna M
  • Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.
    Int J Radiat Oncol Biol Phys Volume: 115 Page(s): 1217 - 1228
    04/01/2023 Authors: Qian DC; Ulrich BC; Peng G; Zhao H; Conneely KN; Miller AH; Bruner DW; Eldridge RC; Wommack EC; Higgins KA
  • Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer.
    Cancer Res Commun Volume: 3 Page(s): 659 - 671
    04/01/2023 Authors: Lang L; Chen F; Li Y; Shay C; Yang F; Dan H; Chen ZG; Saba NF; Teng Y
  • Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
    Nat Med Volume: 29 Page(s): 880 - 887
    04/01/2023 Authors: Saba NF; Steuer CE; Ekpenyong A; McCook-Veal A; Magliocca K; Patel M; Schmitt NC; Stokes W; Bates JE; Rudra S
  • Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A.
    JCO Oncol Pract Volume: 19 Page(s): 194 - 196
    04/01/2023 Authors: Yilmaz E; Ismaila N; Dabney R; Saba NF; Mell LK
  • Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer.
    Cancers (Basel) Volume: 15
    03/24/2023 Authors: Saba NF; Pamulapati S; Patel B; Mody M; Strojan P; Takes R; Mkitie AA; Cohen O; Pace-Asciak P; Vermorken JB
  • Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.
    Int J Radiat Oncol Biol Phys Volume: 115 Page(s): 847 - 860
    03/15/2023 Authors: Gillison ML; Ferris RL; Harris J; Colevas AD; Mell LK; Kong C; Jordan RC; Moore KL; Truong M-T; Kirsch C
  • Radiomics in Hypopharyngeal Cancer Management: A State-of-the-Art Review.
    Biomedicines Volume: 11
    03/06/2023 Authors: Chiesa-Estomba CM; Mayo-Yanez M; Guntinas-Lichius O; Vander-Poorten V; Takes RP; de Bree R; Halmos GB; Saba NF; Nuyts S; Ferlito A
  • Biomarkers predictive of response to pembrolizumab in head and neck cancer.
    Cancer Med Volume: 12 Page(s): 6603 - 6614
    03/01/2023 Authors: Pfister DG; Haddad RI; Worden FP; Weiss J; Mehra R; Chow LQM; Liu SV; Kang H; Saba NF; Wirth LJ
  • Ninety-day mortality following transoral robotic surgery or radiation at Commission on Cancer-accredited facilities.
    Head Neck Volume: 45 Page(s): 658 - 663
    03/01/2023 Authors: Janopaul-Naylor JR; Rupji M; Tobillo RA; Lorenz JW; Switchenko JM; Tian S; Kaka AS; Qian DC; Schlafstein AJ; Steuer CE
  • Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
    J Clin Oncol Volume: 41 Page(s): 1132 - 1146
    02/10/2023 Authors: Yilmaz E; Ismaila N; Bauman JE; Dabney R; Gan G; Jordan R; Kaufman M; Kirtane K; McBride SM; Old MO
  • Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res Volume: 29 Page(s): 560 - 570
    02/01/2023 Authors: Aggarwal C; Saba NF; Algazi A; Sukari A; Seiwert TY; Haigentz M; Porosnicu M; Bonomi M; Boyer J; Esser MT
  • Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Cancers (Basel) Volume: 15
    01/28/2023 Authors: Rodrigo JP; Snchez-Canteli M; Triantafyllou A; de Bree R; Mkitie AA; Franchi A; Hellquist H; Saba NF; Stenman G; Takes RP
  • Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    J Exp Clin Cancer Res Volume: 42 Page(s): 4
    01/05/2023 Authors: Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
  • Oncologic Outcomes After Clinically Node-Negative Salvage Laryngectomy.
    JAMA Otolaryngol Head Neck Surg Volume: 149 Page(s): 24 - 33
    01/01/2023 Authors: Gross JH; Patel MR; Switchenko JM; Chan TG; Baddour HM; Kaka A; Boyce BJ; Saba NF; Beitler JJ; El-Deiry M
  • Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
    J Immunother Cancer Volume: 11
    01/01/2023 Authors: Kansal V; Burnham AJ; Kinney BLC; Saba NF; Paulos C; Lesinski GB; Buchwald ZS; Schmitt NC
  • Proton Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma.
    Int J Part Ther Volume: 9 Page(s): 243 - 252
    01/01/2023 Authors: Mendenhall WM; Beitler JJ; Saba NF; Shaha AR; Nuyts S; Strojan P; Bollen H; Cohen O; Smee R; Ng SP
  • The evolving landscape of salivary gland tumors.
    CA Cancer J Clin Volume: 73 Page(s): 597 - 619
    01/01/2023 Authors: Steuer CE; Hanna GJ; Viswanathan K; Bates JE; Kaka AS; Schmitt NC; Ho AL; Saba NF
  • Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck.
    Front Oncol Volume: 13 Page(s): 1310106
    01/01/2023 Authors: Puttagunta P; Pamulapati SV; Bates JE; Gross JH; Stokes WA; Schmitt NC; Steuer C; Teng Y; Saba NF
  • Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: "Repeat and replicate".
    Cancer Volume: 128 Page(s): 4177 - 4178
    12/15/2022 Authors: Steuer CE; Saba NF
  • Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
    J Natl Cancer Inst Volume: 114 Page(s): 1619 - 1627
    12/08/2022 Authors: Rodriguez CP; Kang H; Geiger JL; Burtness B; Chung CH; Pickering CR; Fakhry C; Le QT; Yom SS; Galloway TJ
  • The impact of operability status on outcomes in patients with T4 larynx cancer undergoing larynx preservation.
    Head Neck Volume: 44 Page(s): 2854 - 2864
    12/01/2022 Authors: Schlafstein AJ; Goyal S; Amini A; Karam SD; Saba NF; Kaka AS; Aiken AH; Beitler JJ; Stokes WA
  • Current Radiotherapy Considerations for Nasopharyngeal Carcinoma.
    Cancers (Basel) Volume: 14
    11/24/2022 Authors: Ng WT; Chow JCH; Beitler JJ; Corry J; Mendenhall W; Lee AWM; Robbins KT; Nuyts S; Saba NF; Smee R
  • Evaluating new treatments for anaplastic thyroid cancer.
    Expert Rev Anticancer Ther Volume: 22 Page(s): 1239 - 1247
    11/01/2022 Authors: Coca-Pelaz A; Rodrigo JP; Lopez F; Shah JP; Silver CE; Al Ghuzlan A; Menke-van der Houven van Oordt CW; Smallridge RC; Shaha AR; Angelos P
  • The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.
    J Natl Cancer Inst Volume: 114 Page(s): 1333 - 1337
    10/06/2022 Authors: Lalonde CS; Teng Y; Burtness BA; Ferris RL; Ahmed R; Saba NF
  • A network analysis of self-reported psychoneurological symptoms in patients with head and neck cancer undergoing intensity-modulated radiotherapy.
    Cancer Volume: 128 Page(s): 3734 - 3743
    10/01/2022 Authors: Lin Y; Bruner DW; Paul S; Miller AH; Saba NF; Higgins KA; Shin DM; Zhang W; Miaskowski C; Xiao C
  • Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
    Oral Oncol Volume: 133 Page(s): 106031
    10/01/2022 Authors: Chow JCH; Lee AWM; Wong CHL; Ng WT; Liu Z; Tay JK; Loh KS; Pace-Asciak P; Cohen O; Corry J
  • The diverse functions of FAT1 in cancer progression: good, bad, or ugly?
    J Exp Clin Cancer Res Volume: 41 Page(s): 248
    08/15/2022 Authors: Chen ZG; Saba NF; Teng Y
  • Chromosome Translocations, Gene Fusions, and Their Molecular Consequences in Pleomorphic Salivary Gland Adenomas.
    Biomedicines Volume: 10
    08/14/2022 Authors: Stenman G; Fehr A; Sklov A; Vander Poorten V; Hellquist H; Mikkelsen LH; Saba NF; Guntinas-Lichius O; Chiesa-Estomba CM; Andersson MK
  • Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply.
    Lancet Volume: 399 Page(s): 2102
    06/04/2022 Authors: Saba NF; Mody MD; Rocco JW; Haddad RI; Yom SS
  • Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res Volume: 28 Page(s): 2329 - 2338
    06/01/2022 Authors: Chung CH; Li J; Steuer CE; Bhateja P; Johnson M; Masannat J; Poole MI; Song F; Hernandez-Prera JC; Molina H
  • T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.
    J Immunother Cancer Volume: 10
    06/01/2022 Authors: Wang X; Muzaffar J; Kirtane K; Song F; Johnson M; Schell MJ; Li J; Yoder SJ; Conejo-Garcia JR; Guevara-Patino JA
  • A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
    Cancers (Basel) Volume: 14
    05/26/2022 Authors: Bauman JE; Chen Z; Zhang C; Ohr JP; Ferris RL; McGorisk GM; Brandt S; Srivatsa S; Chen AY; Steuer CE
  • Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer.
    Cancers (Basel) Volume: 14
    05/10/2022 Authors: Bauman JE; Julian R; Saba NF; Wise-Draper TM; Adkins DR; O'Brien P; Fidler MJ; Gibson MK; Duvvuri U; Heath-Chiozzi M
  • Epidemiology of early esophageal adenocarcinoma.
    Clin Endosc Volume: 55 Page(s): 372 - 380
    05/01/2022 Authors: Hang T-VP; Spiritos Z; Gamboa AM; Chen Z; Force S; Patel V; Chawla S; Keilin S; Saba NF; El-Rayes B
  • Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab.
    Oral Oncol Volume: 127 Page(s): 105787
    04/01/2022 Authors: Glazar DJ; Johnson M; Farinhas J; Steuer CE; Saba NF; Bonomi M; Chung CH; Enderling H
  • TP53 mutations in head and neck cancer.
    Mol Carcinog Volume: 61 Page(s): 385 - 391
    04/01/2022 Authors: Nathan C-A; Khandelwal AR; Wolf GT; Rodrigo JP; Mkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
  • Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
    Oncologist Volume: 27 Page(s): e194 - e198
    03/04/2022 Authors: Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C
  • Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era.
    Cancers (Basel) Volume: 14
    02/25/2022 Authors: Saba NF; Vijayvargiya P; Vermorken JB; Rodrigo JP; Willems SM; Zidar N; de Bree R; Mkitie A; Wolf GT; Argiris A
  • Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas.
    Oncologist Volume: 27 Page(s): 48 - 56
    02/03/2022 Authors: Vijayvargiya P; Trivedi S; Rupji M; Song H; Liu Y; Jiang R; Kaka AS; Chen GZ; Stokes W; Steuer C
  • The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local-regional failures.
    Head Neck Volume: 44 Page(s): 382 - 390
    02/01/2022 Authors: Dhere VR; Escott CE; Tian S; Switchenko JM; Bell JP; Stokes WA; McDonald MW; Magliocca KR; Boyce BJ; Kaka AS
  • ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development.
    J Exp Clin Cancer Res Volume: 41 Page(s): 43
    01/29/2022 Authors: Lang L; Loveless R; Dou J; Lam T; Chen A; Wang F; Sun L; Juarez J; Qin ZS; Saba NF
  • Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
    J Clin Oncol Volume: 40 Page(s): 138 - 149
    01/10/2022 Authors: Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U
  • Cervical Lymph Node Metastases from Central Nervous System Tumors: A Systematic Review.
    Cancer Manag Res Volume: 14 Page(s): 1099 - 1111
    01/01/2022 Authors: Coca-Pelaz A; Bishop JA; Zidar N; Agaimy A; Gebrim EMMS; Mondin V; Cohen O; Strojan P; Rinaldo A; Shaha AR
  • Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management - A Systematic Review.
    Cancer Manag Res Volume: 14 Page(s): 339 - 366
    01/01/2022 Authors: Ng WT; But B; Choi HCW; de Bree R; Lee AWM; Lee VHF; Lpez F; Mkitie AA; Rodrigo JP; Saba NF
  • To Scan or Not to Scan: The Dilemma of Posttreatment Imaging Surveillance of Head and Neck Cancer.
    Pract Radiat Oncol Volume: 12 Page(s): 210 - 214
    01/01/2022 Authors: Janopaul-Naylor JR; Aiken AH; Saba NF; El-Deiry M; Kaka AS; Stokes WA
  • Head and neck cancer.
    Volume: 398 Page(s): 2289 - 2299
    12/18/2021 Authors: Mody MD; Rocco JW; Yom SS; Haddad RI; Saba NF
  • Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer.
    J Exp Clin Cancer Res Volume: 40 Page(s): 393
    12/14/2021 Authors: Lang L; Wang F; Ding Z; Zhao X; Loveless R; Xie J; Shay C; Qiu P; Ke Y; Saba NF
  • De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
    Oral Oncol Volume: 123 Page(s): 105620
    12/01/2021 Authors: Golusinski P; Corry J; Poorten VV; Simo R; Sjgren E; Mkitie A; Kowalski LP; Langendijk J; Braakhuis BJM; Takes RP
  • The Hidden Link of Exosomes to Head and Neck Cancer.
    Cancers (Basel) Volume: 13
    11/19/2021 Authors: Teng Y; Gao L; Loveless R; Rodrigo JP; Strojan P; Willems SM; Nathan C-A; Mkitie AA; Saba NF; Ferlito A
  • Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-Treatment DNA Methylation in Peripheral Blood.
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): S143 - S144
    11/01/2021 Authors: Qian DC; Ulrich BC; Peng G; Zhao H; Conneely KN; Miller AH; Bruner DW; Eldridge RC; Wommack EC; Higgins KA
  • Does Operability Status Influence Outcomes in Patients With T4 Larynx Cancer Undergoing Larynx Preservation?
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): e366
    11/01/2021 Authors: Schlafstein A; Goyal S; Amini A; Karam SD; Saba NF; Kaka AS; Aiken AH; Beitler JJ; Stokes WA
  • CA209-9KY: Phase II Study of IMRT Re-Irradiation and Concurrent/Adjuvant Nivolumab (Nivo) in Patients With Loco Regionally Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC) - Toxicity and Quality of Life (QoL) Results.
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): e361
    11/01/2021 Authors: Saba NF; Wong S; Stokes WA; Rupji M; Liu Y; Rudra S; Bates JE; Steuer C; Remick JS; Cummings K
  • Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC).
    Oral Oncol Volume: 122 Page(s): 105546
    11/01/2021 Authors: Shu L; Wang D; Nannapaneni S; Sun Y; Griffith CC; Wang X; Chen Z; Patel M; El-Deiry M; Shin DM
  • Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival.
    Cancer Epidemiol Biomarkers Prev Volume: 30 Page(s): 1858 - 1866
    10/01/2021 Authors: Eldridge RC; Uppal K; Hayes DN; Smith MR; Hu X; Qin ZS; Beitler JJ; Miller AH; Wommack EC; Higgins KA
  • Cancer of the Paranasal Sinuses.
    Hematol Oncol Clin North Am Volume: 35 Page(s): 949 - 962
    10/01/2021 Authors: Taylor MA; Saba NF
  • Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study.
    Cancer Volume: 127 Page(s): 3361 - 3371
    09/15/2021 Authors: Xiao C; Beitler JJ; Peng G; Levine ME; Conneely KN; Zhao H; Felger JC; Wommack EC; Chico CE; Jeon S
  • Defining HPV-specific B cell responses in patients with head and neck cancer.
    Nature Volume: 597 Page(s): 274 - 278
    09/01/2021 Authors: Wieland A; Patel MR; Cardenas MA; Eberhardt CS; Hudson WH; Obeng RC; Griffith CC; Wang X; Chen ZG; Kissick HT
  • Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016.
    Cancer Med Volume: 10 Page(s): 6070 - 6077
    09/01/2021 Authors: Taylor MA; Switchenko J; Stokes W; Patel MR; McDonald M; Steuer C; Aiken A; Beitler JJ; Shin DM; Saba NF
  • Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer.
    Int J Radiat Oncol Biol Phys Volume: 111 Page(s): 157 - 167
    09/01/2021 Authors: Xiao C; Miller AH; Peng G; Levine ME; Conneely KN; Zhao H; Eldridge RC; Wommack EC; Jeon S; Higgins KA
  • The Proteomic Landscape of Growth Factor Signaling Networks Associated with FAT1 Mutations in Head and Neck Cancers.
    Cancer Res Volume: 81 Page(s): 4402 - 4416
    09/01/2021 Authors: Chen Z; Zhang C; Chen J; Wang D; Tu J; Van Waes C; Saba NF; Chen ZG; Chen Z
  • Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer.
    Nature Volume: 597 Page(s): 279 - 284
    09/01/2021 Authors: Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X
  • Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1.
    Nat Commun Volume: 12 Page(s): 4960
    08/16/2021 Authors: Pan C; Kang J; Hwang JS; Li J; Boese AC; Wang X; Yang L; Boggon TJ; Chen GZ; Saba NF
  • A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma.
    Eur J Cancer Volume: 153 Page(s): 109 - 122
    08/01/2021 Authors: Lee AWM; Lee VHF; Ng W-T; Strojan P; Saba NF; Rinaldo A; Willems SM; Rodrigo JP; Forastiere AA; Ferlito A
  • Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Cancers (Basel) Volume: 13
    07/15/2021 Authors: Patel B; Saba NF
  • Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.
    J Clin Oncol Volume: 39 Page(s): 1856 - 1864
    06/10/2021 Authors: Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn M-J; Boni V; Even C
  • TORS elective lingual tonsillectomy has less acute morbidity than therapeutic base of tongue TORS.
    Oral Oncol Volume: 117 Page(s): 105294
    06/01/2021 Authors: Patel MR; Ottenstein L; Ryan M; Farrell A; Studer M; Baddour HM; Magliocca K; Griffith C; Stokes W; Switchenko J
  • Preoperative chemotherapy for sinonasal squamous cell carcinoma (SNSCC): Time to move closer to a definitive answer.
    Cancer Volume: 127 Page(s): 1734 - 1735
    06/01/2021 Authors: Saba NF
  • The role of the gut microbiome in cancer-related fatigue: pilot study on epigenetic mechanisms.
    Support Care Cancer Volume: 29 Page(s): 3173 - 3182
    06/01/2021 Authors: Xiao C; Fedirko V; Beitler J; Bai J; Peng G; Zhou C; Gu J; Zhao H; Lin I-H; Chico CE
  • Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study.
    Cancers (Basel) Volume: 13
    03/09/2021 Authors: Chung CH; Bonomi M; Steuer CE; Li J; Bhateja P; Johnson M; Masannat J; Song F; Hernandez-Prera JC; Wenig BM
  • Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma.
    JCO Oncol Pract Volume: 17 Page(s): e313 - e322
    03/01/2021 Authors: Marks JA; Switchenko JM; Steuer CE; Ryan M; Patel MR; McDonald MW; Higgins K; Beitler JJ; Shin DM; Gillespie TW
  • Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
    Laryngoscope Volume: 131 Page(s): E921 - E928
    03/01/2021 Authors: Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
  • Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors.
    J Atr Fibrillation Volume: 13 Page(s): 2461
    01/01/2021 Authors: Joseph L; C Nickel A; Patel A; F Saba N; R Leon A; F El-Chami M; M Merchant F
  • Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma.
    PLoS One Volume: 16 Page(s): e0247498
    01/01/2021 Authors: Nannapaneni S; Griffith CC; Magliocca KR; Chen W; Lyu X; Chen Z; Wang D; Wang X; Shin DM; Chen ZG
  • Combinatorial approaches targeting the EGFR family and c-Met in SCCHN.
    Oral Oncol Volume: 112 Page(s): 105074
    01/01/2021 Authors: Wang D; Lu Y; Nannapaneni S; Griffith CC; Steuer C; Qian G; Wang X; Chen Z; Patel M; El-Deiry M
  • Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.
    Oral Oncol Volume: 111 Page(s): 104928
    12/01/2020 Authors: Wolf GT; Liu S; Bellile E; Sartor M; Rozek L; Thomas D; Nguyen A; Zarins K; McHugh JB; INSPIRE Trial Clinical Investigators
  • Narrowband Imaging for p16+ Unknown Primary Squamous Cell Carcinoma Prior to Transoral Robotic Surgery.
    Otolaryngol Head Neck Surg Volume: 163 Page(s): 1198 - 1201
    12/01/2020 Authors: Al-Mulki K; Hamilton J; Kaka AS; Boyce BJ; Baddour HM; El-Deiry M; Solares CA; Magliocca K; Summers K; Aiken A
  • Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma.
    Laryngoscope Volume: 130 Page(s): E850 - E857
    12/01/2020 Authors: Qian DC; Magliocca KR; Aiken AH; Baugnon KL; Brandon DC; Stokes WA; McDonald MW; Patel MR; Baddour HM; Kaka AS
  • Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck.
    Clin Cancer Res Volume: 26 Page(s): 5860 - 5868
    11/15/2020 Authors: Shin DM; Nannapaneni S; Patel MR; Shi Q; Liu Y; Chen Z; Chen AY; El-Deiry MW; Beitler JJ; Steuer CE
  • Electronic Cigarettes and Head and Neck Cancer Risk-Current State of Art.
    Cancers (Basel) Volume: 12
    11/05/2020 Authors: Szukalska M; Szyfter K; Florek E; Rodrigo JP; Rinaldo A; Mkitie AA; Strojan P; Takes RP; Surez C; Saba NF
  • An update on the immune landscape in lung and head and neck cancers.
    CA Cancer J Clin Volume: 70 Page(s): 505 - 517
    11/01/2020 Authors: Carlisle JW; Steuer CE; Owonikoko TK; Saba NF
  • A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311.
    Oral Oncol Volume: 110 Page(s): 104797
    11/01/2020 Authors: Ferris RL; Flamand Y; Holsinger FC; Weinstein GS; Quon H; Mehra R; Garcia JJ; Hinni ML; Gross ND; Sturgis EM
  • Gut Microbiome Associated with the Psychoneurological Symptom Cluster in Patients with Head and Neck Cancers.
    Cancers (Basel) Volume: 12
    09/06/2020 Authors: Bai J; Bruner DW; Fedirko V; Beitler JJ; Zhou C; Gu J; Zhao H; Lin I-H; Chico CE; Higgins KA
  • Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?
    AJNR Am J Neuroradiol Volume: 41 Page(s): 1238 - 1244
    07/01/2020 Authors: Gore A; Baugnon K; Beitler J; Saba NF; Patel MR; Wu X; Boyce BJ; Aiken AH
  • Association Among Glucocorticoid Receptor Sensitivity, Fatigue, and Inflammation in Patients With Head and Neck Cancer.
    Psychosom Med Volume: 82 Page(s): 508 - 516
    06/01/2020 Authors: Xiao C; Eldridge RC; Beitler JJ; Higgins KA; Chico CE; Felger JC; Wommack EC; Knobf T; Saba NF; Shin DM
  • Trimodality Therapy in the Treatment of Stage III N2-Positive Non-Small Cell Lung Cancer: A National Cancer Database Analysis.
    Oncologist Volume: 25 Page(s): e964 - e975
    06/01/2020 Authors: Behera M; Steuer CE; Liu Y; Fernandez F; Fu C; Higgins KA; Gillespie TW; Pakkala S; Pillai RN; Force S
  • Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV-Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis.
    JCO Oncol Pract Volume: 16 Page(s): e476 - e487
    06/01/2020 Authors: Bean MB; Switchenko JM; Steuer CE; Patel M; Higgins K; McDonald M; Chen GZ; Beitler JJ; Shin DM; Gillespie T
  • Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer.
    Vaccines (Basel) Volume: 8
    04/14/2020 Authors: Bommireddy R; Munoz LE; Kumari A; Huang L; Fan Y; Monterroza L; Pack CD; Ramachandiran S; Reddy SJC; Kim J
  • A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting.
    Mol Cancer Ther Volume: 19 Page(s): 999 - 1007
    04/01/2020 Authors: Shu L; Wang D; Saba NF; Chen ZG
  • Perioperative Antibiotics in Clean-Contaminated Head and Neck Surgery: A Systematic Review and Meta-Analysis.
    Adv Ther Volume: 37 Page(s): 1360 - 1380
    04/01/2020 Authors: Vander Poorten V; Uyttebroek S; Robbins KT; Rodrigo JP; de Bree R; Laenen A; F Saba N; Suarez C; Mkitie A; Rinaldo A
  • Current management of stage IV nasopharyngeal carcinoma without distant metastasis.
    Cancer Treat Rev Volume: 85 Page(s): 101995
    04/01/2020 Authors: Ng WT; Corry J; Langendijk JA; Lee AWM; Mkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Smee R
  • Exhaled breath analysis in the diagnosis of head and neck cancer.
    Head Neck Volume: 42 Page(s): 787 - 793
    04/01/2020 Authors: Mkitie AA; Almangush A; Youssef O; Metsl M; Siln S; Nixon IJ; Haigentz M; Rodrigo JP; Saba NF; Vander Poorten V
  • Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.
    Head Neck Volume: 42 Page(s): 678 - 687
    04/01/2020 Authors: Tian S; Switchenko JM; Fei T; Press RH; Abugideiri M; Saba NF; Owonikoko TK; Chen AY; Beitler JJ; Curran WJ
  • Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment.
    Curr Treat Options Oncol Volume: 21 Page(s): 4
    01/16/2020 Authors: Mody MD; Saba NF
  • RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies.
    Front Genet Volume: 11 Page(s): 598118
    01/01/2020 Authors: van de Stolpe A; Verhaegh W; Blay J-Y; Ma CX; Pauwels P; Pegram M; Prenen H; De Ruysscher D; Saba NF; Slovin SF
  • Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
    PLoS One Volume: 15 Page(s): e0238497
    01/01/2020 Authors: Saba NF; Dinasarapu AR; Magliocca KR; Dwivedi B; Seby S; Qin ZS; Patel M; Griffith CC; Wang X; El-Deiry M
  • Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data.
    Oncologist Volume: 24 Page(s): 1562 - 1569
    12/01/2019 Authors: Bean MB; Liu Y; Jiang R; Steuer CE; Patel M; McDonald MW; Higgins KA; Beitler JJ; Shin DM; Saba NF
  • Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
    J Clin Oncol Volume: 37 Page(s): 3266 - 3274
    12/01/2019 Authors: Argiris A; Li S; Savvides P; Ohr JP; Gilbert J; Levine MA; Chakravarti A; Haigentz M; Saba NF; Ikpeazu CV
  • Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.
    Mol Cancer Ther Volume: 18 Page(s): 1909 - 1915
    11/01/2019 Authors: Saba NF; Chen ZG; Haigentz M; Bossi P; Rinaldo A; Rodrigo JP; Mkitie AA; Takes RP; Strojan P; Vermorken JB
  • Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: APropensity Score-Matched Analysis of the National Cancer Database.
    Clin Lung Cancer Volume: 20 Page(s): 484 - 493.e6
    11/01/2019 Authors: Tian S; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
  • Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
    Volume: 30
    10/01/2019 Authors: Trivedi S; Steuer CE; Tkaczuk AT; Shin DM; Klein A; Saba NF
  • Tumor membrane vesicle-based vaccine inhibits growth of squamous cell carcinoma of head and neck in mice
    Volume: 49 Page(s): 1693 - 1693
    10/01/2019 Authors: Bommireddy R; Munoz L; Pack C; Ramachandiran S; Reddy S; Kim J; Chen G; Saba N; Shin D; Selvaraj P
  • Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.
    J Clin Invest Volume: 129 Page(s): 4110 - 4123
    10/01/2019 Authors: Pan C; Chun J; Li D; Boese AC; Li J; Kang J; Umano A; Jiang Y; Song L; Magliocca KR
  • Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Cancer Volume: 125 Page(s): 3208 - 3218
    09/15/2019 Authors: Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F
  • Management of locally recurrent nasopharyngeal carcinoma.
    Cancer Treat Rev Volume: 79 Page(s): 101890
    09/01/2019 Authors: Lee AWM; Ng WT; Chan JYW; Corry J; Mkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Strojan P
  • Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
    Lancet Oncol Volume: 20 Page(s): 1295 - 1305
    09/01/2019 Authors: Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K
  • Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
    Oral Oncol Volume: 96 Page(s): 7 - 14
    09/01/2019 Authors: Saba NF; Blumenschein G; Guigay J; Licitra L; Fayette J; Harrington KJ; Kiyota N; Gillison ML; Ferris RL; Jayaprakash V
  • Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Clin Cancer Res Volume: 25 Page(s): 5221 - 5230
    09/01/2019 Authors: Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R
  • Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma.
    Head Neck Pathol Volume: 13 Page(s): 304 - 312
    09/01/2019 Authors: Lesinski GB; Nannapaneni S; Griffith CC; Patel M; Chen W; Chen Z; Ahmed R; Wieland A; Shin DM; Chen ZG
  • Prognostic value of radiographically defined extranodal extension in human papillomavirus-associated locally advanced oropharyngeal carcinoma.
    Head Neck Volume: 41 Page(s): 3056 - 3063
    09/01/2019 Authors: Tian S; Ferris MJ; Switchenko JM; Magliocca KR; Cassidy RJ; Jhaveri J; Aiken AH; Baugnon KL; Hudgins PA; Kendi ATK
  • Survival outcomes by high-risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity-scored analysis of the National Cancer Data Base.
    Cancer Volume: 125 Page(s): 2782 - 2793
    08/15/2019 Authors: Tian S; Switchenko JM; Jhaveri J; Cassidy RJ; Ferris MJ; Press RH; Pfister NT; Patel MR; Saba NF; McDonald MW
  • Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis.
    Cancer Treat Rev Volume: 78 Page(s): 42 - 51
    08/01/2019 Authors: Strojan P; Hernandez-Prera JC; Beitler JJ; Eisbruch A; Saba NF; Mendenhall WM; Nieto CS; Smee R; Rinaldo A; Ferlito A
  • TMV vaccine inhibits growth of squamous cell carcinoma of head and neck in mice
    Volume: 79
    07/01/2019 Authors: Bommireddy R; Munoz L; Pack CD; Ramachandiran S; Reddy SJC; Kim J; Chen G; Saba NF; Shin DM; Selvaraj P
  • Effective treatment of squamous cell carcinoma of the head and neck (HNSCC) using a combined regimen of tipifarnib and cetuximab
    Volume: 79
    07/01/2019 Authors: Shu L; Wang D; Nannapaneni S; Shin DM; Saba NF; Chen GZ
  • Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
    Volume: 79
    07/01/2019 Authors: Lesinski GB; Fisher TL; Evans EE; Leonard JE; Pastore DR; Mallow C; Smith E; Zauderer M; Steuer C; Saba NF
  • Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis.
    Volume: 37
    05/20/2019 Authors: Trivedi S; Song H; Liu Y; Steuer CE; Stokes W; Kaka A; Patel M; Chen ZG; Shin DM; Aiken A
  • Socioeconomic contributions to clinical outcome by HPV status in squamous cell carcinomas of the head and neck (SCCHN):An analysis of NCDB.
    Volume: 37
    05/20/2019 Authors: Marks JA; Switchenko JM; Steuer CE; Herrin S; Ryan MA; Patel M; El-Deiry M; Beitler JJ; Shin DM; Gillespie TW
  • Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck.
    Volume: 37
    05/20/2019 Authors: Shin DM; Beitler JJ; El-Deiry M; Steuer CE; Chen AY; Baddour HM; Chen ZG; Roser S; Magliocca KR; Patel M
  • Factors associated with metastatic presentation in HPV-related squamous cell carcinoma of the head and neck (SCCHN): A National Cancer Database (NCDB) analysis.
    Volume: 37
    05/20/2019 Authors: Bean MB; Switchenko JM; Steuer CE; Patel M; El-Deiry M; Higgins KA; McDonald MW; Chen ZG; Beitler JJ; Shin DM
  • A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
    Volume: 37
    05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G
  • Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance.
    J Clin Invest Volume: 129 Page(s): 2431 - 2445
    05/13/2019 Authors: Pan C; Jin L; Wang X; Li Y; Chun J; Boese AC; Li D; Kang H-B; Zhang G; Zhou L
  • Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature.
    Crit Rev Oncol Hematol Volume: 137 Page(s): 84 - 91
    05/01/2019 Authors: Bossi P; Alfieri S; Strojan P; Takes RP; Lpez F; Mkitie A; Saba NF; Rodrigo JP; Bradford C; Suarez C
  • Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Volume: 41 Page(s): 1490 - 1498
    05/01/2019 Authors: Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R
  • Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.
    Am J Clin Oncol Volume: 42 Page(s): 331 - 336
    04/01/2019 Authors: Saba NF; Force S; Staley C; Fernandez F; Willingham F; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
  • Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx.
    Cancer Volume: 125 Page(s): 704 - 711
    03/01/2019 Authors: Beitler JJ; Switchenko JM; Dignam JJ; McDonald MW; Saba NF; Shin DM; Magliocca KR; Cassidy RJ; El-Deiry MW; Patel MR
  • Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
    JAMA Oncol Volume: 5 Page(s): 195 - 203
    02/01/2019 Authors: Siu LL; Even C; Mesa R; Remenar E; Daste A; Delord J-P; Krauss J; Saba NF; Nabell L; Ready NE
  • Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas.
    Laryngoscope Volume: 129 Page(s): 377 - 386
    02/01/2019 Authors: Cassidy RJ; Switchenko JM; El-Deiry MW; Belcher RH; Zhong J; Steuer CE; Saba NF; McDonald MW; Yu DS; Gillespie TW
  • Prognosis of subglottic carcinoma: Is it really worse?
    Head Neck Volume: 41 Page(s): 511 - 521
    02/01/2019 Authors: Coskun H; Mendenhall WM; Rinaldo A; Rodrigo JP; Surez C; Strojan P; Lpez F; Mondin V; Saba NF; Shaha AR
  • Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis.
    Oncology Volume: 97 Page(s): 49 - 58
    01/01/2019 Authors: Gupta DR; Liu Y; Jiang R; Walid S; Higgins K; Landry J; McDonald M; Willingham FF; El-Rayes BF; Saba NF
  • Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma.
    Nutr Cancer Volume: 71 Page(s): 772 - 780
    01/01/2019 Authors: Rozek LS; Virani S; Bellile EL; Taylor JMG; Sartor MA; Zarins KR; Virani A; Cote C; Worden FP; Mark MEP
  • Prognostic implications of peritumoral vasculature in head and neck cancer.
    Cancer Med Volume: 8 Page(s): 147 - 154
    01/01/2019 Authors: Evans M; Baddour HM; Magliocca KR; Mller S; Nannapaneni S; Chen AY; Kim S; Chen Z; Shin DM; Wang AY
  • T4 Laryngeal Cancer With Good Function: Should We Be Reluctant to Treat Without Surgery?
    Int J Radiat Oncol Biol Phys Volume: 102 Page(s): 1400 - 1403
    12/01/2018 Authors: Beitler JJ; Ridge JA; Vermorken JB; Bradford CR; Strojan P; Saba NF; Surez C; Rodrigo JP; Rinaldo A; Chen AY
  • Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer.
    Brain Behav Immun Volume: 74 Page(s): 291 - 295
    11/01/2018 Authors: Xiao C; Beitler JJ; Higgins KA; Wommack EC; Saba NF; Shin DM; Bruner DW; Miller AH; Cole S
  • Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
    JAMA Oncol Volume: 4 Page(s): 1583 - 1588
    11/01/2018 Authors: Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M
  • Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
    Cancer Volume: 124 Page(s): 4163 - 4164
    11/01/2018 Authors: Saba NF; Mendenhall WM; Hutcheson K; Surez C; Wolf G; Ferlito A
  • Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation
    Volume: 102 Page(s): E27 - E27
    11/01/2018 Authors: Saba NF; Force S; Staley CA; Fernandez F; Willingham FF; Pickens A; Cardona K; Chen Z; Goff L; Cardin D
  • Survival Advantage to Combined Modality Therapy Seen in Multiple Subgroups Within Anaplastic Thyroid Carcinoma: A Propensity-Score Matched Analysis of the National Cancer Data Base
    Volume: 102 Page(s): E356 - E357
    11/01/2018 Authors: Tian S; Switchenko J; Fei T; Press RH; Abugideiri M; Saba NF; Owonikoko TK; Chen AY; Beitler JJ; Curran WJ
  • Incidence of Cancer Treatment-Induced Arrhythmia Associated With Novel Targeted Chemotherapeutic Agents.
    J Am Heart Assoc Volume: 7 Page(s): e010101
    10/16/2018 Authors: Nickel AC; Patel A; Saba NF; Leon AR; El-Chami MF; Merchant FM
  • Latent class analysis of fatigue in patients with head and neck cancer
    Volume: 27 Page(s): S63 - S63
    10/01/2018 Authors: Xiao C; Eldridge R; Higgins K; Saba N; Shin D; Miller A; Bruner D; Beitler J
  • The Epidemiology of Esophageal Adenocarcinoma in the United States
    Volume: 113 Page(s): S185 - S186
    10/01/2018 Authors: Hang T-VP; Spiritos Z; Gamboa A; Chen Z; Force S; Keilin S; Saba N; El-Rayes B; Cai Q; Willingham F
  • CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
    Oncologist Volume: 23 Page(s): 1079 - 1082
    09/01/2018 Authors: Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C
  • MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
    Cancer Cell Volume: 34 Page(s): 315 - 330.e7
    08/13/2018 Authors: Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang H-B; Song L; Wang D
  • The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma.
    Cancers (Basel) Volume: 10
    08/10/2018 Authors: Hamoir M; Schmitz S; Suarez C; Strojan P; Hutcheson KA; Rodrigo JP; Mendenhall WM; Simo R; Saba NF; D'Cruz AK
  • Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer.
    Cancer Volume: 124 Page(s): 3163 - 3170
    08/01/2018 Authors: Xiao C; Beitler JJ; Higgins KA; Glazer T; Huynh LK; Paul S; Felger JC; Wommack EC; Saba NF; Shin DM
  • Time to Rethink Our Strategy With a Preoperative Intensification Approach.
    Int J Radiat Oncol Biol Phys Volume: 101 Page(s): 762
    07/15/2018 Authors: Saba NF
  • Systemic therapy in non-conventional cancers of the larynx.
    Oral Oncol Volume: 82 Page(s): 61 - 68
    07/01/2018 Authors: Tan E; Mody MD; Saba NF
  • Predicting fatigue levels of head and neck cancer patients with gene expression using machine learning
    Volume: 78
    07/01/2018 Authors: Eldridge RC; Miller AH; Bruner DW; Beitler JJ; Higgins KA; Wommack EC; Linh KH; Saba NF; Shin DM; Xiao C
  • Effective reduction of PD-L1 expression by simultaneous blockade of EGFR and HER3 (ErbB3) in head and neck cancer
    Volume: 78
    07/01/2018 Authors: Chen ZG; Wang D; Griffith CC; Nannapaneni S; Steuer C; Patel MR; El-Deiry MW; Wang X; Zhang Y; Chen Z
  • Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Oral Oncol Volume: 81 Page(s): 45 - 51
    06/01/2018 Authors: Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C
  • A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).
    Volume: 36
    05/20/2018 Authors: Bauman JE; Saba NF; Adkins D; Wang Y; He Y; Paradise E; Cohen RB
  • Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas
    Volume: 100 Page(s): 1382 - 1382
    04/01/2018 Authors: Cassidy RJ; Switchenko J; El-Deiry MW; Belcher RH; Zhong J; Steuer C; Saba NF; McDonald MW; Yu DS; Gillespie T
  • The Effect of Hospital Volume and Insurance Status on Overall Survival in Sinonasal Carcinoma: A National Cancer Database (NCDB) Analysis
    Volume: 100 Page(s): 1385 - 1386
    04/01/2018 Authors: Trivedi S; Switchenko J; Patel MR; Steuer C; El-Deiry MW; Higgins KA; Solares CA; McDonald MW; Shin DM; Gillespie T
  • INCIDENCE OF CANCER TREATMENT-INDUCED ARRHYTHMIA ASSOCIATED WITH NOVEL TARGETED CHEMOTHERAPEUTIC AGENTS
    Volume: 71 Page(s): 273 - 273
    03/10/2018 Authors: Nickel A; El-Chami M; Saba NF; Leon A; Merchant F
  • A Review of Photodynamic Therapy for Neoplasms of the Head and Neck.
    Adv Ther Volume: 35 Page(s): 324 - 340
    03/01/2018 Authors: Civantos FJ; Karakullukcu B; Biel M; Silver CE; Rinaldo A; Saba NF; Takes RP; Vander Poorten V; Ferlito A
  • A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
    Mol Cancer Ther Volume: 17 Page(s): 710 - 716
    03/01/2018 Authors: Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM
  • Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.
    Clin Cancer Res Volume: 24 Page(s): 858 - 869
    02/15/2018 Authors: Wang X; Beitler JJ; Huang W; Chen G; Qian G; Magliocca K; Patel MR; Chen AY; Zhang J; Nannapaneni S
  • Deformable Registration of Histological Cancer Margins to Gross Hyperspectral Images using Demons.
    Proc SPIE Int Soc Opt Eng Volume: 10581
    02/01/2018 Authors: Halicek M; Little JV; Wang X; Chen ZG; Patel M; Griffith CC; El-Deiry MW; Saba NF; Chen AY; Fei B
  • Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome.
    Adv Ther Volume: 35 Page(s): 153 - 160
    02/01/2018 Authors: Coca-Pelaz A; Takes RP; Hutcheson K; Saba NF; Haigentz M; Bradford CR; de Bree R; Strojan P; Lund VJ; Mendenhall WM
  • Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease?
    Cancers Head Neck Volume: 3 Page(s): 8
    01/01/2018 Authors: Saba NF; Li S; Hussain ZA; Subramanian R; Califano JA; Chung CH
  • Nivolumab (Nivo) vs Investigator's Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CheckMate 141): Outcomes in First-line (1L) R/M Patients (Pts) and Updated Safety and Efficacy
    Volume: 41 Page(s): 96 - 96
    01/01/2018 Authors: Kasper S; Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Vokes EE; Even C
  • Malignancies of the Paranasal Sinuses and Skull Base
    Page(s): 359 - 370
    01/01/2018 Authors: Osborn HA; Park JC; Saba NF; Blanchard P; Lin DT
  • Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer.
    ORL J Otorhinolaryngol Relat Spec Volume: 80 Page(s): 85 - 95
    01/01/2018 Authors: Patel MR; Hudgins PA; Beitler JJ; Magliocca KR; Griffith CC; Liu Y; Bougnon K; El-Deiry M; Saba NF; Aiken AH
  • Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.
    Head Neck Volume: 39 Page(s): 2433 - 2443
    12/01/2017 Authors: Zhang H; Kim S; Chen Z; Nannapaneni S; Chen AY; Moore CE; Sica G; Mosunjac M; Nguyen MLT; D'Souza G
  • Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy
    Volume: 13 Page(s): 144 - 144
    11/01/2017 Authors: Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C
  • Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Volume: 13 Page(s): 141 - 141
    11/01/2017 Authors: Concha-Benavente F; Gillison ML; Blumenschien G; Harrington KJ; Fayette J; Colevas AD; Licitra L; Kasper S; Even C; Worden F
  • Nivolumab vs Investigator'S Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
    Volume: 13 Page(s): 143 - 143
    11/01/2017 Authors: Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R
  • Refining the predictors of outcome in patients with resectable esophageal cancer.
    Cancer Volume: 123 Page(s): 4097 - 4098
    11/01/2017 Authors: Saba NF
  • Resilience and biomarkers of health risk in Black smokers and nonsmokers.
    Health Psychol Volume: 36 Page(s): 1047 - 1058
    11/01/2017 Authors: Berg CJ; Haardrfer R; McBride CM; Kilaru V; Ressler KJ; Wingo AP; Saba NF; Payne JB; Smith A
  • Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.
    Head Neck Volume: 39 Page(s): 2329 - 2349
    11/01/2017 Authors: de Bree R; Wolf GT; de Keizer B; Nixon IJ; Hartl DM; Forastiere AA; Haigentz M; Rinaldo A; Rodrigo JP; Saba NF
  • The Relationship Between Radiation Dose And Overall Survival In Cervical Esophageal Cancer: An NCDB Analysis
    Volume: 99 Page(s): E178 - E179
    10/01/2017 Authors: Patel PR; McDonald MW; Aiello A; Liu Y; Saba NF; Beitler JJ; Higgins KA
  • The Impact of Histologic Phenotype in the Treatment of Sinonasal Cancer.
    Adv Ther Volume: 34 Page(s): 2181 - 2198
    10/01/2017 Authors: Lpez F; Lund VJ; Surez C; Snyderman CH; Saba NF; Robbins KT; Vander Poorten V; Strojan P; Mendenhall WM; Rinaldo A
  • HPV status is associated with fatigue at one year post IMRT for patients with head and neck cancer
    Volume: 26 Page(s): 45 - 45
    10/01/2017 Authors: Xiao C; Beitler JJ; Higgins KA; Saba NF; Shin DM; Linh KH; Glazer T; Miller AH; Bruner DW
  • Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Cancer Volume: 123 Page(s): 3476 - 3485
    09/15/2017 Authors: Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K
  • Nivolumab vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141
    Volume: 28
    09/01/2017 Authors: Licitra L; Ferris RL; Blumenschein G; Harrington KJ; Guigay J; Kasper S; Saba NF; Haddad R; Kiyota N; Monga M
  • Treatment beyond progression with nivolumab (nivo) in patients with recurrent or metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the phase 3 CheckMate 141 study
    Volume: 40 Page(s): 250 - +
    09/01/2017 Authors: Kasper S; Haddad R; Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Vokes EE; Worden F
  • Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    JAMA Oncol Volume: 3 Page(s): 1120 - 1129
    08/01/2017 Authors: Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ
  • Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Lancet Oncol Volume: 18 Page(s): 1104 - 1115
    08/01/2017 Authors: Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F
  • How phenotype guides management of non-conventional squamous cell carcinomas of the larynx?
    Eur Arch Otorhinolaryngol Volume: 274 Page(s): 2709 - 2726
    07/01/2017 Authors: Lpez F; Williams MD; Cardesa A; Hunt JL; Strojan P; Rinaldo A; Nixon IJ; Rodrigo JP; Saba NF; Mendenhall WM
  • Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
    Crit Rev Oncol Hematol Volume: 115 Page(s): 50 - 58
    07/01/2017 Authors: Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M
  • Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma.
    AJNR Am J Neuroradiol Volume: 38 Page(s): 1193 - 1199
    06/01/2017 Authors: Krieger DA; Hudgins PA; Nayak GK; Baugnon KL; Corey AS; Patel MR; Beitler JJ; Saba NF; Liu Y; Aiken AH
  • Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).
    Volume: 35
    05/20/2017 Authors: Concha-Benavente F; Gillison ML; Blumenschein GR; Harrington K; Fayette J; Colevas AD; Licitra L; Kasper S; Even C; Worden FP
  • Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial.
    Volume: 35
    05/20/2017 Authors: Argiris A; Li S; Savvides P; Ohr J; Gilbert J; Levine MA; Haigentz M; Saba NF; Chakravarti A; Ikpeazu C
  • A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease: The PATHWay Study.
    Volume: 35
    05/20/2017 Authors: Baum J; Karrison T; Yokes EE; Cohen RB; De Souza JA; Aggarwal C; Saloura V; Agrawal N; Saba NF; Langer CJ
  • Patterns of head and neck cancer incidence, mortality, and survival in the US Hispanic population.
    Volume: 35
    05/20/2017 Authors: Oh MS; Jiang R; Liu Y; Zhu X; Saba NF; Henriquez OA
  • Optimal thoracic radiation dose in limited stage small cell lung cancer.
    Volume: 35
    05/20/2017 Authors: Behera M; Zhang X; Jiang R; Pillai RN; Patel PR; Pakkala S; Steuer CE; Saba NF; Owonikoko TK; Belani C
  • Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation.
    Volume: 35
    05/20/2017 Authors: Higgins KA; Zhang X; Jiang R; Pillai RN; Owonikoko TK; Steuer CE; Saba NF; Pakkala S; Patel PR; Belani CP
  • Enrollment into molecular selection trials and impact on patient disposition.
    Volume: 35
    05/20/2017 Authors: Harvey RD; Steuer CE; Judson EC; Lewis CM; Collins HH; Saba NF; El-Rayes BF; Curran WJ; Rannalingam SS; Pentz RD
  • Small cell carcinoma of the head and neck: Incidence and survival trends based on the Surveillance and Epidemiologic and End Results (SEER) analysis.
    Volume: 35
    05/20/2017 Authors: Bean M; Goodman M; Steuer CE; Patel M; McDonald MW; Higgins KA; Owonikoko TK; Beitler JJ; Shin DM; Saba NF
  • Institutional treatment volume and outcomes in salivary gland cancer.
    Volume: 35
    05/20/2017 Authors: Steuer CE; Switchenko JM; Griffith CC; Patel M; Cassidy RJ; Gillespie TW; McDonald MW; Higgins KA; Beitler JJ; Owonikoko TK
  • Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).
    Volume: 35
    05/20/2017 Authors: Saba NF; Force SD; Staley CA; Fernandez FG; Willingham FF; Allan P; Cardona K; Chen Z; Cardin DB; Lambright E
  • Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
    J Clin Oncol Volume: 35 Page(s): 1542 - 1549
    05/10/2017 Authors: Bauml J; Seiwert TY; Pfister DG; Worden F; Liu SV; Gilbert J; Saba NF; Weiss J; Wirth L; Sukari A
  • Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell LungCancer.
    Clin Lung Cancer Volume: 18 Page(s): e203 - e210
    05/01/2017 Authors: Saba NF; Wang Y; Fu H; Koenig L; Khuri FR; Shin DM; Chen ZG
  • Nasal juvenile angiofibroma: Current perspectives with emphasis on management.
    Head Neck Volume: 39 Page(s): 1033 - 1045
    05/01/2017 Authors: Lpez F; Triantafyllou A; Snyderman CH; Hunt JL; Surez C; Lund VJ; Strojan P; Saba NF; Nixon IJ; Devaney KO
  • Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.
    Volume: 18 Page(s): 286 - 292
    05/01/2017 Authors: Steuer CE; Behera M; Liu Y; Fu C; Gillespie TW; Saba NF; Shin DM; Pillai RN; Pakkala S; Owonikoko TK
  • Otorhinolaryngological Toxicities of New Drugs in Oncology.
    Adv Ther Volume: 34 Page(s): 866 - 894
    04/01/2017 Authors: Hartl DM; Morel D; Saavedra E; Massard C; Rinaldo A; Saba NF; Ferlito A; Soria J-C
  • Association of Lymphovascular Space Invasion With Locoregional Failure and Survival in Patients With Node-Negative Oral Tongue Cancers.
    JAMA Otolaryngol Head Neck Surg Volume: 143 Page(s): 382 - 388
    04/01/2017 Authors: Cassidy RJ; Switchenko JM; Jegadeesh N; Sayan M; Ferris MJ; Eaton BR; Higgins KA; Wadsworth JT; Magliocca KR; Saba NF
  • Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).
    Volume: 35
    03/01/2017 Authors: Ferris RL; Concha-Benavente F; Blumenschein GR; Harrington KJ; Fayette J; Colevas AD; Licitra LF; Kasper S; Even C; Gillison ML
  • ACR appropriateness criteria nasal cavity and paranasal sinus cancers.
    Head Neck Volume: 39 Page(s): 407 - 418
    03/01/2017 Authors: Siddiqui F; Smith RV; Yom SS; Beitler JJ; Busse PM; Cooper JS; Hanna EY; Jones CU; Koyfman SA; Quon H
  • Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials.
    Auris Nasus Larynx Volume: 44 Page(s): 18 - 25
    02/01/2017 Authors: Sanabria A; Chaves ALF; Kowalski LP; Wolf GT; Saba NF; Forastiere AA; Beitler JJ; Nibu K-I; Bradford CR; Surez C
  • CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer.
    AJNR Am J Neuroradiol Volume: 38 Page(s): 364 - 370
    02/01/2017 Authors: Junn JC; Baugnon KL; Lacayo EA; Hudgins PA; Patel MR; Magliocca KR; Corey AS; El-Deiry M; Wadsworth JT; Beitler JJ
  • Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor.
    Oncology Volume: 93 Page(s): 336 - 342
    01/01/2017 Authors: Evans M; Liu Y; Chen C; Steuer C; Cassidy R; Landry J; Higgins K; Beitler JJ; Willingham F; Owonikoko TK
  • Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.
    Am J Nucl Med Mol Imaging Volume: 7 Page(s): 174 - 180
    01/01/2017 Authors: Kendi AT; Brandon D; Switchenko J; Wadsworth JT; El-Deiry MW; Saba NF; Schuster DM; Subramaniam RM
  • Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).
    Front Oncol Volume: 7 Page(s): 31
    01/01/2017 Authors: Saba NF
  • Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
    Volume: 12 Page(s): S470 - S470
    01/01/2017 Authors: Behera M; Gillespie T; Liu Y; Jia Y; Higgins K; Steuer C; Saba N; Shin D; Pakkala S; Pillai R
  • An update on larynx cancer.
    CA Cancer J Clin Volume: 67 Page(s): 31 - 50
    01/01/2017 Authors: Steuer CE; El-Deiry M; Parks JR; Higgins KA; Saba NF
  • A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Cancer Volume: 122 Page(s): 3641 - 3649
    12/01/2016 Authors: Jimeno A; Posner MR; Wirth LJ; Saba NF; Cohen RB; Popa EC; Argiris A; Grossmann KF; Sukari A; Wilson D
  • The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma.
    J Clin Med Volume: 5
    11/14/2016 Authors: Shaib WL; Nammour JPA; Gill H; Mody M; Saba NF
  • Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    N Engl J Med Volume: 375 Page(s): 1856 - 1867
    11/10/2016 Authors: Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C
  • Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we?
    Eur Arch Otorhinolaryngol Volume: 273 Page(s): 2877 - 2894
    10/01/2016 Authors: Samuels SE; Eisbruch A; Beitler JJ; Corry J; Bradford CR; Saba NF; van den Brekel MWM; Smee R; Strojan P; Surez C
  • Risk factors for fatigue changes during acute phase of IMRT for patients with head and neck cancer
    QUALITY OF LIFE RESEARCH Volume: 25 Page(s): 156 - 156
    10/01/2016 Authors: Xiao C; Beitler JJ; Higgins KA; Saba NF; Glazer T; Kowalski J; Miller AH; Bruner DW
  • Lymphovascular Space Invasion Is Independently Predictive of Local and Regional Failure and Reduced Survival in Node-Negative Oral Tongue Cancers
    Volume: 96 Page(s): S85 - S85
    10/01/2016 Authors: Cassidy RJ; Switchenko J; Jegadeesh N; Ferris MJ; Eaton BR; Higgins KA; Wadsworth JT; Saba NF; Beitler JJ
  • Persistent Fatigue Is Associated With Persistent Peripheral Inflammation in Patients With Squamous Cell Carcinoma of the Head and Neck Cancer up to 3 Months Post-Intensity Modulated Radiation Therapy
    Volume: 96 Page(s): E348 - E348
    10/01/2016 Authors: Xiao C; Beitler JJ; Higgins KA; Glazer T; Wommack E; Shin DM; Saba NF; Bruner DW; Miller AH
  • Persistent Fatigue Is Associated With Persistent Peripheral Inflammation in Patients With Squamous Cell Carcinoma of the Head and Neck Cancer up to 3 Months Post-Intensity Modulated Radiation Therapy.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E348
    10/01/2016 Authors: Xiao C; Beitler JJ; Higgins KA; Glazer T; Wommack E; Shin DM; Saba NF; Watkins Bruner D; Miller AH
  • Lymphovascular Space Invasion Is Independently Predictive of Local and Regional Failure and Reduced Survival in Node-Negative Oral Tongue Cancers.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): S85
    10/01/2016 Authors: Cassidy RJ; Switchenko J; Jegadeesh N; Ferris MJ; Eaton BR; Higgins KA; Wadsworth JT; Saba NF; Beitler JJ
  • Lymphovascular Space Invasion Is Independently Predictive of Local and Regional Failure and Reduced Survival in Node-Negative Oral Tongue Cancers
    Volume: 96 Page(s): S85 - S85
    10/01/2016 Authors: Cassidy RJ; Switchenko J; Jegadeesh N; Ferris MJ; Eaton BR; Higgins KA; Wadsworth JT; Saba NF; Beitler JJ
  • Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors?
    AJR Am J Roentgenol Volume: 207 Page(s): 635 - 640
    09/01/2016 Authors: Kendi ATK; Magliocca KR; Corey A; Galt JR; Switchenko J; Wadsworth JT; El-Deiry MW; Schuster DM; Saba NF; Hudgins PA
  • ACR Appropriateness Criteria() Locoregional therapy for resectable oropharyngeal squamous cell carcinomas.
    Head Neck Volume: 38 Page(s): 1299 - 1309
    09/01/2016 Authors: Beitler JJ; Quon H; Jones CU; Salama JK; Busse PM; Cooper JS; Koyfman SA; Ridge JA; Saba NF; Siddiqui F
  • The Challenges of Laryngeal Preservation-Is It the Systemic Agent or the Proper Sequence of Therapy?
    JAMA Otolaryngol Head Neck Surg Volume: 142 Page(s): 849 - 850
    09/01/2016 Authors: Saba NF; Shin DM
  • The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
    JAMA Otolaryngol Head Neck Surg Volume: 142 Page(s): 898 - 905
    09/01/2016 Authors: Mody MD; Gill HS; Saba NF
  • Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation.
    Eur J Cancer Volume: 65 Page(s): 21 - 32
    09/01/2016 Authors: Qian G; Wang D; Magliocca KR; Hu Z; Nannapaneni S; Kim S; Chen Z; Sun S-Y; Shin DM; Saba NF
  • Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement.
    Cancer Volume: 122 Page(s): 2150 - 2157
    07/15/2016 Authors: Gamboa AM; Kim S; Force SD; Staley CA; Woods KE; Kooby DA; Maithel SK; Luke JA; Shaffer KM; Dacha S
  • Biomarker quantification by multiplexed quantum dot technology for predicting lymph node metastasis and prognosis in head and neck cancer.
    Oncotarget Volume: 7 Page(s): 44676 - 44685
    07/12/2016 Authors: Hu Z; Qian G; Mller S; Xu J; Saba NF; Kim S; Chen Z; Jiang N; Wang D; Zhang H
  • A novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular -catenin expression.
    J Oral Pathol Med Volume: 45 Page(s): 399 - 408
    07/01/2016 Authors: Qian G; Hu Z; Xu H; Mller S; Wang D; Zhang H; Kim S; Chen Z; Saba NF; Shin DM
  • HER3 targeting sensitizes HNSCC to cetuximab - evidence from cell line and patient derived xenograft (PDX) models
    Volume: 76
    07/01/2016 Authors: Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Chen Z; Patel MR; El-Deiry MW; Wadsworth JT; Shin DM
  • Survivin contributes to radiation resistance in head and neck cancer through regulation of DNA damage repair
    Volume: 76
    07/01/2016 Authors: Wang X; Beitler JJ; Huang W; Chen G; Nannapaneni S; Saba NF; Deng X; Chen ZG; Shin DM
  • ACR Appropriateness criteria for nasopharyngeal carcinoma.
    Head Neck Volume: 38 Page(s): 979 - 986
    07/01/2016 Authors: Saba NF; Salama JK; Beitler JJ; Busse PM; Cooper JS; Jones CU; Koyfman S; Quon H; Ridge JA; Siddiqui F
  • Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out?
    J Clin Oncol Volume: 34 Page(s): 2072 - 2073
    06/10/2016 Authors: Saba NF; Wong SJ
  • Impact of neck failure on survival in older patients with differentiated thyroid cancer.
    Head Neck Volume: 38 Page(s): 919 - 924
    06/01/2016 Authors: Marcus DM; Jiang R; Ward KC; Higgins KA; Saba NF; Wadsworth JT; Beitler JJ
  • Clinical outcomes in elderly patients with human papillomavirus-positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy.
    Head Neck Volume: 38 Page(s): 846 - 851
    06/01/2016 Authors: Hanasoge S; Magliocca KR; Switchenko JM; Saba NF; Wadsworth JT; El-Deiry MW; Shin DM; Khuri F; Beitler JJ; Higgins KA
  • An integrated workflow to identify targetable mutations in FFPE samples of HNSCC.
    Volume: 34
    05/20/2016 Authors: Saba NF; Magliocca KR; Patel M; Steuer CE; Newman S; Zhang H; El-Deiry M; Wadsworth JT; Kowalski J; Shin DM
  • A correlative analysis of PDL-1, PD-1, and EGFR, HER2, HER3 expression in oropharyngeal squamous cell carcinoma (OPSCC).
    Volume: 34
    05/20/2016 Authors: Steuer CE; Griffith CC; Liu Y; Magliocca KR; Patel M; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
  • Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB).
    Volume: 34
    05/20/2016 Authors: Behera M; Gillespie TW; Liu Y; Jia Y; Higgins KA; Steuer CE; Saba NF; Shin DM; Pakkala S; Pillai RN
  • Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).
    Volume: 34
    05/20/2016 Authors: Bauml J; Seiwert TY; Pfister DG; Worden FP; Liu SV; Gilbert J; Saba NF; Weiss J; Wirth LJ; Sukari A
  • Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base
    Volume: 34
    05/20/2016 Authors: Naik K; Liu Y; Goodman M; Gillespie TW; El-Rayes BF; Pickens A; Force S; Steuer CE; Owonikoko TK; Ramalingam SS
  • Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.
    Volume: 34
    05/20/2016 Authors: Evans M; Liu Y; Chen C; Gillespie TW; Steuer CE; Owonikoko TK; Ramalingam SS; Beitler JJ; El-Rayes BF; Fernandez F
  • Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
    J Transl Med Volume: 14 Page(s): 111
    05/03/2016 Authors: Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R
  • External Validation of Therapy Response Interpretation Criteria (Hopkins Criteria) with inter-reader reliability, accuracy and Progression free survival outcomes
    JOURNAL OF NUCLEAR MEDICINE Volume: 57
    05/01/2016 Authors: Kendi ATK; Brandon D; Switchenko J; Wadsworth J; El-Deiry M; Saba N; Schuster D; Subramaniam R
  • Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.
    Head Neck Volume: 38 Suppl 1 Page(s): E2151 - E2158
    04/01/2016 Authors: Strojan P; Vermorken JB; Beitler JJ; Saba NF; Haigentz M; Bossi P; Worden FP; Langendijk JA; Eisbruch A; Mendenhall WM
  • Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    Support Care Cancer Volume: 24 Page(s): 1789 - 1793
    04/01/2016 Authors: McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
  • Radiation Dose Escalation Is Associated With Improved Survival in Cervical Esophageal Cancer
    Volume: 94 Page(s): 891 - 891
    03/15/2016 Authors: Jegadeesh N; Liu Y; Oyelade B; Gillespie T; Cassidy RJ; Fernandez F; Saba N; Beitler JJ; Landry JC
  • Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?
    Ann Transl Med Volume: 4 Page(s): 80
    02/01/2016 Authors: Chapman CH; Saba NF; Yom SS
  • ACR Appropriateness Criteria() Aggressive Nonmelanomatous Skin Cancer of the Head and Neck.
    Head Neck Volume: 38 Page(s): 175 - 182
    02/01/2016 Authors: Koyfman SA; Cooper JS; Beitler JJ; Busse PM; Jones CU; McDonald MW; Quon H; Ridge JA; Saba NF; Salama JK
  • Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration?
    Eur J Radiol Volume: 85 Page(s): 319 - 323
    02/01/2016 Authors: Kendi AT; Corey A; Magliocca KR; Galt JR; Zhang C; Chen Z; Higgins K; Beitler JJ; Wadsworth JT; El-Deiry MW
  • Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy.
    Brain Behav Immun Volume: 52 Page(s): 145 - 152
    02/01/2016 Authors: Xiao C; Beitler JJ; Higgins KA; Conneely K; Dwivedi B; Felger J; Wommack EC; Shin DM; Saba NF; Ong LY
  • Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
    Ann Oncol Volume: 27 Page(s): 318 - 323
    02/01/2016 Authors: Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF
  • Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer.
    Case Rep Hematol Volume: 2016 Page(s): 8581421
    01/01/2016 Authors: Mody MD; Gill HS; Higgins KA; Saba NF; Kota VK
  • Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy.
    Front Oncol Volume: 6 Page(s): 272
    01/01/2016 Authors: Sayan M; Cassidy RJ; Switchenko JM; Kayode OA; Saba NF; Steuer CE; Shin DM; Wadsworth JT; El-Deiry M; Patel M
  • Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline.
    PLoS One Volume: 11 Page(s): e0168450
    01/01/2016 Authors: Wang D; Peng S; Amin ARMR; Rahman MA; Nannapaneni S; Liu Y; Shin DM; Saba NF; Eichler JF; Chen ZG
  • Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
    Cancer Volume: 122 Page(s): 50 - 60
    01/01/2016 Authors: Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS
  • The role of systemic therapy in the management of sinonasal cancer: A critical review.
    Cancer Treat Rev Volume: 41 Page(s): 836 - 843
    12/01/2015 Authors: Bossi P; Saba NF; Vermorken JB; Strojan P; Pala L; de Bree R; Rodrigo JP; Lopez F; Hanna EY; Haigentz M
  • Targeting HER (ERBB) signaling in head and neck cancer: An essential update.
    Mol Aspects Med Volume: 45 Page(s): 74 - 86
    11/01/2015 Authors: Zhang J; Saba NF; Chen GZ; Shin DM
  • Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Cancer Volume: 121 Page(s): 3600 - 3611
    10/15/2015 Authors: Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR
  • Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S545 - S545
    09/01/2015 Authors: Kumar M; Ragin C; Zhang C; Chen Z; Han EJ; Ernani V; Behera M; Steuer C; Saba N; Shin D
  • A Systematic Review of Carboplatin-Paclitaxel versus Cisplatin-Etoposide Concurrent with Thoracic Radiation for Stage III NSCLC Patients
    JOURNAL OF THORACIC ONCOLOGY Volume: 10 Page(s): S212 - S212
    09/01/2015 Authors: Steuer C; Behera M; Higgins KA; Saba N; Shin D; Pakkala S; Pillai R; Owonikoko TK; Curran WJ; Belani CP
  • Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review.
    J Thorac Oncol Volume: 10 Page(s): 1142 - 1147
    08/01/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Steuer C; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
  • PIK3CA/BRAF mutations negatively affect outcome of patients with KRAS wild-type metastatic colorectal cancer treated with front line anti-EGFR monoclonal antibodies: Meta-analysis results
    Volume: 75
    08/01/2015 Authors: Mohamed A; Schrapp K; Attumi T; Saba NF; El-Rayes BF
  • Human papillomavirus 16 oncoprotein E6 upregulates c-Met partially through p53 in squamous cell carcinoma of the head and neck
    Volume: 75
    08/01/2015 Authors: Qian G; Wang D; Magliocca KR; Duggal P; Nannapaneni S; Kim S; Chen Z; Shin DM; Saba NF; Chen ZG
  • Targeting RRM2 by siRNA inhibits cellular invasion and represents a rational approach for inhibition of metastasis of head and neck and lung cancers
    Volume: 75
    08/01/2015 Authors: Rahman MA; Amin ARMR; Zhang J; Nannapaneni S; Saba NF; Chen ZG; Shin DM
  • Current treatment of T1N0 squamous cell carcinoma of the glottic larynx.
    Eur Arch Otorhinolaryngol Volume: 272 Page(s): 1821 - 1824
    08/01/2015 Authors: Mendenhall WM; Takes RP; Shah JP; Bradley PJ; Beitler JJ; Strojan P; Surez C; Rodrigo JP; Saba NF; Rinaldo A
  • Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2.
    Apoptosis Volume: 20 Page(s): 986 - 995
    07/01/2015 Authors: Haque A; Rahman MA; Chen ZG; Saba NF; Khuri FR; Shin DM; Ruhul Amin ARM
  • Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis.
    Oral Oncol Volume: 51 Page(s): 586 - 592
    06/01/2015 Authors: Joseph LJ; Goodman M; Higgins K; Pilai R; Ramalingam SS; Magliocca K; Patel MR; El-Deiry M; Wadsworth JT; Owonikoko TK
  • 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers?
    Eur J Radiol Volume: 84 Page(s): 1171 - 1176
    06/01/2015 Authors: Kendi AT; Corey A; Magliocca KR; Nickleach DC; Galt J; Switchenko JM; El-Deiry MW; Wadsworth JT; Hudgins PA; Saba NF
  • Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.
    Head Neck Pathol Volume: 9 Page(s): 223 - 235
    06/01/2015 Authors: Saba NF; Wilson M; Doho G; DaSilva J; Benjamin Isett R; Newman S; Chen ZG; Magliocca K; Rossi MR
  • Lymph node ratio influence on risk of head and neck cancer locoregional recurrence after initial surgical resection: implications for adjuvant therapy.
    Head Neck Volume: 37 Page(s): 777 - 782
    06/01/2015 Authors: Prabhu RS; Hanasoge S; Magliocca KR; Hall WA; Chen SA; Higgins KA; Saba NF; El-Deiry M; Grist W; Wadsworth JT
  • Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data
    Volume: 33
    05/20/2015 Authors: Saba NF; Newman S; Rossi MR; Steuer CE; Zhang H; Patel M; Wadsworth JT; El-Deiry M; Magliocca KR; Owonikoko TK
  • Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes.
    Volume: 33
    05/20/2015 Authors: Owonikoko TK; Nelson M; Park SY; Kim S; Steuer CE; Behera M; Chen Z; Han E; Kumar M; Ernani V
  • Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
    Volume: 33
    05/20/2015 Authors: Behera M; Steuer CE; Fernandez F; Liu Y; Fu C; Gillespie TW; Higgins KA; Saba NF; Pillai RN; Force S
  • Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis.
    Volume: 33
    05/20/2015 Authors: Behera M; Pillai RN; Owonikoko TK; Pakkala S; Steuer CE; Saba NF; Shin DM; Belani CP; Khuri FR; Ramalingam SS
  • Dual targeting of EGFR and HER3 with cetuximab and MM-121/SAR256212 in HNSCC patient derived xenograft (PDX) models.
    Volume: 33
    05/20/2015 Authors: Saba NF; Wang D; Qian G; Zhang H; Patel M; El-Deiry M; Wadsworth JT; Magliocca KR; Nannapaneni S; Shin DM
  • A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res Volume: 21 Page(s): 1859 - 1868
    04/15/2015 Authors: Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD
  • Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis.
    Lung Cancer Volume: 88 Page(s): 80 - 84
    04/01/2015 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai R; Saba NF; Shin DM; Owonikoko TK; Khuri FR
  • A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol Volume: 51 Page(s): 376 - 382
    04/01/2015 Authors: Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J
  • A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res Volume: 21 Page(s): 1566 - 1573
    04/01/2015 Authors: Galloway TJ; Wirth LJ; Colevas AD; Gilbert J; Bauman JE; Saba NF; Raben D; Mehra R; Ma AW; Atoyan R
  • Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status?
    Clin Nucl Med Volume: 40 Page(s): e196 - e200
    03/01/2015 Authors: Kendi ATK; Magliocca K; Corey A; Nickleach DC; Galt J; Higgins K; Beitler JJ; El-Deiry MW; Wadsworth JT; Hudgins PA
  • Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis.
    J Thorac Oncol Volume: 10 Page(s): 479 - 485
    03/01/2015 Authors: Steuer CE; Behera M; Kim S; Chen Z; Saba NF; Pillai RN; Owonikoko TK; Khuri FR; Ramalingam SS
  • Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention".
    Oral Oncol Volume: 51 Page(s): 112 - 118
    02/01/2015 Authors: Saba NF; Haigentz M; Vermorken JB; Strojan P; Bossi P; Rinaldo A; Takes RP; Ferlito A
  • Human papillomavirus 16 oncoprotein regulates the translocation of -catenin via the activation of epidermal growth factor receptor.
    Cancer Volume: 121 Page(s): 214 - 225
    01/15/2015 Authors: Hu Z; Mller S; Qian G; Xu J; Kim S; Chen Z; Jiang N; Wang D; Zhang H; Saba NF
  • Oral Cavity Cancer: Risk Factors, Pathology, and Management.
    Oncology Volume: 89 Page(s): 187 - 195
    01/01/2015 Authors: Ernani V; Saba NF
  • Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Cancer Volume: 120 Page(s): 3940 - 3951
    12/15/2014 Authors: Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J
  • Pre-medications for cetuximab induced infusion reactions - commentary.
    Oral Oncol Volume: 50 Page(s): e71
    12/01/2014 Authors: McKibbin T; Donald Harvey R; Saba NF
  • Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
    Cancer Chemother Pharmacol Volume: 74 Page(s): 1015 - 1022
    11/01/2014 Authors: Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R
  • EGFR targeted iron-oxide nanoparticles for photodynamic therapy in head and neck cancer
    Volume: 74
    10/01/2014 Authors: Wang D; Qin X; Qian G; Halig L; Fei B; Chen Z; Chen ZG; Saba NF; Shin DM; Xu H
  • Enhancing specificity in predication of human papillomavirus associated oropharyngeal squamous cell carcinoma by combining biomarkers p16 and beta-catenin
    Volume: 74
    10/01/2014 Authors: Qian G; Xu H; Hu Z; Kim S; Wang D; Zhang H; Chen Z; Muller S; Saba N; Shin DM
  • Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review.
    Oral Oncol Volume: 50 Page(s): 888 - 894
    09/01/2014 Authors: Behera M; Owonikoko TK; Kim S; Chen Z; Higgins K; Ramalingam SS; Shin DM; Khuri FR; Beitler JJ; Saba NF
  • Squamous Cell Carcinoma of the Oral Tongue: Exploring New Trends
    Volume: 90 Page(s): S508 - S509
    09/01/2014 Authors: Cassidy RJ; Switchenko JM; Wadsworth JT; El-Deity M; Saba NF; Higgins KA; Beitler JJ
  • Increased Fatigue Is Associated With TNF and NF kappa B-Regulated Inflammatory Signaling in Patients With Head and Neck Cancer Receiving IMRT
    Volume: 90 Page(s): S571 - S571
    09/01/2014 Authors: Xiao C; Beitler JJ; Higgins KA; Felger J; Ong LY; Shin DM; Saba NF; Bruner DW; Miller AH
  • Targeted therapies in metastatic esophageal cancer: advances over the past decade.
    Crit Rev Oncol Hematol Volume: 91 Page(s): 186 - 196
    08/01/2014 Authors: Mohamed A; El-Rayes B; Khuri FR; Saba NF
  • Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma.
    Mol Cancer Ther Volume: 13 Page(s): 1826 - 1836
    07/01/2014 Authors: Jiang N; Wang D; Hu Z; Shin HJC; Qian G; Rahman MA; Zhang H; Amin ARMR; Nannapaneni S; Wang X
  • ACR Appropriateness Criteria thyroid carcinoma.
    Oral Oncol Volume: 50 Page(s): 577 - 586
    06/01/2014 Authors: Salama JK; Golden DW; Yom SS; Garg MK; Lawson J; McDonald MW; Quon H; Ridge JA; Saba N; Smith RV
  • Esophagogastric junction and gastric adenocarcinoma: current challenges and future directions.
    Oncology (Williston Park) Volume: 28 Page(s): 520 - 521
    06/01/2014 Authors: Saba NF
  • The impact of locoregional recurrence on survival in older patients with differentiated thyroid cancer
    Volume: 32
    05/20/2014 Authors: Marcus DM; Jiang R; Ward KC; Higgins KA; Saba NF; Wadsworth T; Beitier JJ
  • Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis.
    Volume: 32
    05/20/2014 Authors: Joseph L; Goodman M; Higgins KA; Pilai R; Ramalingam SS; Owonikoko TK; Beitler JJ; Shin DM; Khuri FR; Saba NF
  • Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy
    Volume: 32
    05/20/2014 Authors: Behera M; Ragin C; Kim S; Chen Z; Steuer CE; Saba NF; Pillal RN; Belani CP; Ramalingam SS; Khuri FR
  • Predictive value of gene expression signatures in premalignant lesions of the head and neck for response to cheinoprevention with EGFR and COX-2 inhibitors.
    Volume: 32
    05/20/2014 Authors: Saba NF; Rossi MR; Dwivedi B; Switchenko JM; Magllocca KR; Ramalingam SS; Owonlkoko TK; Khuri FR; Chen ZG; Kowalski J
  • Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis
    Volume: 32
    05/20/2014 Authors: Steuer CE; Behera M; Kim S; Patel N; Chen Z; Pillai RN; Saba NF; Shin DM; Owonlkoko TK; Khuri FR
  • Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC).
    Volume: 32
    05/20/2014 Authors: Saba NF; Qian G; Ning J; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG
  • Transcriptional profiling of Tu212 cell line treated with EGCG and resveratrol to identify actionable targets for adjuvant therapy
    Volume: 32
    05/20/2014 Authors: Shin DM; Dwivedi B; Amin RARM; Haque AM; Saba NF; Rossl MR; Chen ZG; Kowalski J
  • Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck
    Volume: 32
    05/20/2014 Authors: Jimeno A; Posner MR; Weiss J; Wirth LJ; Saba NF; Cohen RB; Popa EC; Argiris A; Grossmann KF; Sukari A
  • Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States
    Volume: 146 Page(s): S566 - S567
    05/01/2014 Authors: Gamboa AM; Kim S; Chen Z; Woods KE; Keilin S; Cai Q; Saba N; El-Rayes B; Willingham FF
  • Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
    Cancer Prev Res (Phila) Volume: 7 Page(s): 283 - 291
    03/01/2014 Authors: Saba NF; Hurwitz SJ; Kono SA; Yang CS; Zhao Y; Chen Z; Sica G; Mller S; Moreno-Williams R; Lewis M
  • Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
    Head Neck Pathol Volume: 8 Page(s): 66 - 72
    03/01/2014 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Owonikoko TK; Sarlis NJ; Eggers C; Phelan V; Grist WJ
  • Accuracy of computed tomography for predicting pathologic nodal extracapsular extension in patients with head-and-neck cancer undergoing initial surgical resection.
    Int J Radiat Oncol Biol Phys Volume: 88 Page(s): 122 - 129
    01/01/2014 Authors: Prabhu RS; Magliocca KR; Hanasoge S; Aiken AH; Hudgins PA; Hall WA; Chen SA; Eaton BR; Higgins KA; Saba NF
  • American College of Radiology Appropriateness Criteria() treatment of stage I T1 glottic cancer.
    Head Neck Volume: 36 Page(s): 3 - 8
    01/01/2014 Authors: Ridge JA; Lawson J; Yom SS; Garg MK; McDonald MW; Quon H; Saba N; Salama JK; Smith RV; Worden F
  • Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States.
    Cancer Volume: 119 Page(s): 4020 - 4027
    11/15/2013 Authors: Wang Z; Goodman M; Saba N; El-Rayes BF
  • A PHASE IB PREOPERATIVE PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF EVEROLIMUS IN OPERABLE NON SMALL CELL LUNG CANCER
    JOURNAL OF THORACIC ONCOLOGY Volume: 8 Page(s): S628 - S629
    11/01/2013 Authors: Owonikoko TK; Miller DL; Force S; Sica G; Saba NF; Kono SA; Behera M; Lewis C; Chen Z; Pickens A
  • A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck
    MOLECULAR CANCER THERAPEUTICS Volume: 12
    11/01/2013 Authors: Jimeno A; Galloway T; Wirth L; Gilbert J; Saba N; Bauman J; Colevas D; Mehra R; Raben D; Lai C-J
  • Association of Preoperative Radiographic Nodal Status in Addition to Traditional Pathologic Factors With Outcomes in Patients With Laryngeal or Oral Cavity Cancer Managed With Initial Surgery
    Volume: 87 Page(s): S429 - S429
    10/01/2013 Authors: Prabhu RS; Hanasoge S; Magliocca KR; Hudgins PA; Higgins KA; Chen AY; Grist WJ; Wadsworth JT; Saba NF; Beitler JJ
  • Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009.
    Cancer Volume: 119 Page(s): 2602 - 2610
    07/15/2013 Authors: Ansa B; Goodman M; Ward K; Kono SA; Owonikoko TK; Higgins K; Beitler JJ; Grist W; Wadsworth T; El-Deiry M
  • Paranasal Sinus Squamous Cell Carcinoma Incidence and Survival Based on Surveillance, Epidemiology, and End Results Data, 1973 to 2009
    CANCER Volume: 119 Page(s): 2602 - 2610
    07/15/2013 Authors: Ansa B; Goodman M; Ward K; Kono SA; Owonikoko TK; Higgins K; Beitler JJ; Grist W; Wadsworth T; El-Deiry M
  • Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.
    J Gastrointest Cancer Volume: 44 Page(s): 143 - 151
    06/01/2013 Authors: Carr JS; Zafar SF; Saba N; Khuri FR; El-Rayes BF
  • Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study.
    Volume: 31
    05/20/2013 Authors: Saba NF; Kono SA; Mendel JR; Hurwitz SJ; Owonikoko TK; Lewis CM; Harvey D; Rogerio JW; Chen Z; Wadsworth T
  • Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Volume: 31
    05/20/2013 Authors: Gilbert J; Schell MJ; Zhao X; Murphy BA; Tanvetyanon T; Hayes DN; Haigentz M; Saba NF; Nieva JJ; Perez J
  • Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Volume: 31
    05/20/2013 Authors: Jimeno A; Wirth LJ; Posner MR; Cohen RB; Weiss J; Popa EC; Saba NF; Grossmann KF; Sukari A; Cohen EEW
  • Heat shock protein 90 (HSP90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): An in vitro analysis with a focus on p16 status
    Volume: 31
    05/20/2013 Authors: Patel KR; Wen J; Muller S; Gao J; Diaz R; Saba NF
  • A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States.
    Volume: 31
    05/20/2013 Authors: Kang H; Kim S; Chen Z; El-Rayes BF; Brandes JC; Saba NF; Khuri FR; Ramalingam SS; Owonikoko TK
  • Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review.
    Volume: 31
    05/20/2013 Authors: Behera M; Pillai RN; Owonikoko TK; Kim S; Chen Z; Saba NF; Belani CP; Khuri FR; Ramalingam SS
  • Subceliular translocation of beta-catenin and its relationship with EGFR activation in HPV16 positive OPSCC
    Volume: 73
    04/15/2013 Authors: Hu Z; Jiang N; Muller S; Saba N; Wang D; Zhang H; Shin DM; Chen ZG
  • Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer.
    Volume: 73
    04/15/2013 Authors: Jiang N; Wang D; Hu Z; Rahman AM; Zhang H; Amin RA; Wang X; Chen Z; Dong SM; Garcia G
  • Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
    Clin Cancer Res Volume: 19 Page(s): 1244 - 1256
    03/01/2013 Authors: Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin ARMR; Mller S; Lewis M; Sica G; Kono S
  • Reply, contralateral irradiation for T(limited)N2bM0 lateralized tonsil cancer.
    Head Neck Volume: 35 Page(s): 465 - 466
    03/01/2013 Authors: Garg MK; Ridge JA; Yom SS; McDonald MW; Quon H; Smith RV; Yeung AR; Lawson J; Saba N; Salama JK
  • Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
    J Thorac Oncol Volume: 8 Page(s): 369 - 372
    03/01/2013 Authors: Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z
  • Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
    Oncologist Volume: 18 Page(s): 1262 - 1269
    01/01/2013 Authors: Owonikoko TK; Chowdry RP; Chen Z; Kim S; Saba NF; Shin DM; Khuri FR
  • Bortezomib in plasmablastic lymphoma: a case report and review of the literature.
    Onkologie Volume: 36 Page(s): 287 - 291
    01/01/2013 Authors: Saba NS; Dang D; Saba J; Cao C; Janbain M; Maalouf B; Safah H
  • Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis.
    Oncologist Volume: 18 Page(s): 600 - 610
    01/01/2013 Authors: Owonikoko TK; Ragin C; Chen Z; Kim S; Behera M; Brandes JC; Saba NF; Pentz R; Ramalingam SS; Khuri FR
  • Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data.
    Cancer Volume: 118 Page(s): 4444 - 4451
    09/15/2012 Authors: Ellington CL; Goodman M; Kono SA; Grist W; Wadsworth T; Chen AY; Owonikoko T; Ramalingam S; Shin DM; Khuri FR
  • HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?
    Head Neck Pathol Volume: 6 Page(s): 336 - 344
    09/01/2012 Authors: Mller S; Khuri FR; Kono SA; Beitler JJ; Shin DM; Saba NF
  • Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer.
    Eur J Cancer Volume: 48 Page(s): 1682 - 1691
    07/01/2012 Authors: Xu J; Mller S; Nannapaneni S; Pan L; Wang Y; Peng X; Wang D; Tighiouart M; Chen Z; Saba NF
  • Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN)
    Volume: 30
    05/20/2012 Authors: Saba NF; Magliocca KR; Kim S; Muller S; Chen Z; Eggers C; Phelan VH; Kono SA; Owonikoko TK; Ramalingam SS
  • A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
    Volume: 30
    05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF
  • Paranasal sinus squamous cell carcinomas (PNSSCC) incidence and survival trends.
    Volume: 30
    05/20/2012 Authors: Ansa B; Goodman M; Ward K; Kono SA; Kunle T; Grist OW; Wadsworth T; El-Deiry M; Chen AY; Ramalingam SS
  • ACR Appropriateness Criteria ipsilateral radiation for squamous cell carcinoma of the tonsil.
    Head Neck Volume: 34 Page(s): 613 - 616
    05/01/2012 Authors: Expert Panel on Radiation Oncology--Head & Neck Cancer:; Yeung AR; Garg MK; Lawson J; McDonald MW; Quon H; Ridge JA; Saba N; Salama JK; Smith RV
  • Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Mahaseth H; Nagaraju GP; Diaz R; Taliaferro-Smith LD; Landry JC; Saba NF; El-Rayes BF
  • Prognostic significance of nuclear factor kappa B expression in human papillomavirus-associated oropharyngeal cancer
    CANCER RESEARCH Volume: 72
    04/15/2012 Authors: Zhang H; Hu Z; Phelan V; Liu Y; Muller S; Saba NF; Beitler JJ; Khuri FR; Chen GZ; Shin DM
  • Human immunodeficiency virus-associated lung cancer in the era of highly active antiretroviral therapy.
    Cancer Volume: 118 Page(s): 164 - 172
    01/01/2012 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JR; Saba NR; Shin DM; Curran WJ; Khuri FR
  • EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.
    Chemother Res Pract Volume: 2012 Page(s): 901320
    01/01/2012 Authors: Kono SA; Haigentz M; Yom SS; Saba N
  • Advances in Targeting HER3 as an Anticancer Therapy.
    Chemother Res Pract Volume: 2012 Page(s): 817304
    01/01/2012 Authors: Jiang N; Saba NF; Chen ZG
  • Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.
    J Oncol Volume: 2012 Page(s): 521215
    01/01/2012 Authors: Shaib W; Kono S; Saba N
  • Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors.
    Chemother Res Pract Volume: 2012 Page(s): 291421
    01/01/2012 Authors: Saba NF; Yom SS; Haigentz M; El-Rayes B
  • Patterns of extralaryngeal spread of laryngeal cancer: thyroid cartilage penetration occurs in a minority of patients with extralaryngeal spread of laryngeal squamous cell cancers.
    Cancer Volume: 117 Page(s): 5047 - 5051
    11/15/2011 Authors: Chen SA; Muller S; Chen AY; Hudgins PA; Shin DM; Khuri F; Saba NF; Beitler JJ
  • Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
    Cancer Volume: 117 Page(s): 4049 - 4059
    09/01/2011 Authors: Kauh J; Chanel-Vos C; Escuin D; Fanucchi MP; Harvey RD; Saba N; Shin DM; Gal A; Pan L; Kutner M
  • ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.
    Int J Radiat Oncol Biol Phys Volume: 80 Page(s): 1292 - 1298
    08/01/2011 Authors: McDonald MW; Lawson J; Garg MK; Quon H; Ridge JA; Saba N; Salama JK; Smith RV; Yeung AR; Yom SS
  • ACR appropriateness criteria adjuvant therapy for resected squamous cell carcinoma of the head and neck.
    Oral Oncol Volume: 47 Page(s): 554 - 559
    07/01/2011 Authors: Expert Panel on Radiation Oncology-Head and Neck; Salama JK; Saba N; Quon H; Garg MK; Lawson J; McDonald MW; Ridge JA; Smith RV; Yeung AR
  • ANALYSIS OF MTOR SIGNALING PATHWAY BIOMARKERS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH EVEROLIMUS AND DOCETAXEL IN A PHASE II CLINICAL TRIAL.
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S1039 - S1040
    06/01/2011 Authors: Owonikoko TK; Ramalingam S; Subramanian J; Sica G; Chen Z; Behera M; Rogerio J; Saba N; Tighiouart M; Gal A
  • A PHASE IB WINDOW OF OPPORTUNITY CLINICAL STUDY WITH EVEROLIMUS IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
    JOURNAL OF THORACIC ONCOLOGY Volume: 6 Page(s): S967 - S968
    06/01/2011 Authors: Owonikoko TK; Force S; Sica G; Bechara R; Harvey RD; Sun S-Y; Saba N; Rogerio J; Gal A; Kono S
  • Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study.
    J Clin Oncol Volume: 29 Page(s): e13601
    05/20/2011 Authors: Khuri FR; Owonikoko TK; Subramanian J; Sica G; Behera M; Saba NF; Chen Z; Tighiouart M; Shin DM; Sun S
  • Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
    J Clin Oncol Volume: 29 Page(s): 7602
    05/20/2011 Authors: Owonikoko TK; Behera M; Tran HN; Chen Z; Chowdry RP; Saba NF; Ramalingam SS; Khuri FR
  • Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
    J Clin Oncol Volume: 29 Page(s): e14569
    05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
  • Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 29
    05/20/2011 Authors: Saba NF; Kim HM; El-Rayes BF; Kono SA; Ramalingam SS; Owonikoko TK; Landry JC; Miller DL; Shin DM; Khuri FR
  • Inhibition of head and neck squamous cell carcinoma growth by combination treatment of erlotinib and celecoxib: Potential chemopreventive agents
    CANCER RESEARCH Volume: 71
    04/15/2011 Authors: Zhang H; Nannapaneni S; Chen Z; Saba N; Khuri FR; Chen GZ; Shin DM
  • Nanotechnology and drug delivery: an update in oncology.
    Pharmaceutics Volume: 3 Page(s): 171 - 185
    04/14/2011 Authors: Jones T; Saba N
  • Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and end results program-based analysis.
    Oncology Volume: 81 Page(s): 12 - 20
    01/01/2011 Authors: Saba NF; Goodman M; Ward K; Flowers C; Ramalingam S; Owonikoko T; Chen A; Grist W; Wadsworth T; Beitler JJ
  • Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Cancer Volume: 116 Page(s): 3903 - 3909
    08/15/2010 Authors: Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun S-Y; Strychor S; Tighiouart M; Egorin MJ
  • Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Saba NF; Muller S; Chen AY; Grist W; Gibson K; Nannapaneni S; Yang CS; Khuri FR; Chen ZG; Shin DM
  • Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck cancer
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Chen ZG; Nannapaneni S; Muller S; Saba NF; Tighiouart M; Pan L; Shin DM
  • Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Owonikoko TK; Ramalingam SS; Behera M; Brandes JC; Saba NF; Bhimani C; Harichand-Herdt S; Shin DM; Khuri FR; Ragin C
  • HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Pakkala S; Chen Z; Rimland D; Owonikoko TK; Gunthel C; Brandes JC; Saba NF; Curran WJ; Khuri FR; Ramalingam SS
  • Acetylated tubulin (AT) levels predicts response to TPF chemotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC)
    CANCER RESEARCH Volume: 70
    04/01/2010 Authors: Saba NF; Marcus A; Beitler JJ; Muller S; Eggers C; Grist W; Chen A; Chen Z; Shin DM; Khuri FR
  • ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas.
    Curr Probl Cancer Volume: 34 Page(s): 175 - 192
    01/01/2010 Authors: Quon H; Yom SS; Garg MK; Lawson J; McDonald MW; Ridge JA; Saba N; Salama J; Smith R; Yeung AR
  • Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: a retrospective single-institution analysis.
    Head Neck Volume: 31 Page(s): 1447 - 1455
    11/01/2009 Authors: Saba NF; Edelman S; Tighiouart M; Gaultney J; Davis LW; Khuri FR; Chen A; Grist W; Shin DM
  • Phase 2 study of ABT-869 in combination with Carboplatin/Paclitaxel (CP) in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC): lead-in cohort results
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S706 - S706
    09/01/2009 Authors: Ramalingam S; Owonikoko T; Khuri F; Saba N; Wallace J; Qian J; Gupta N; Ricker J; Carlson D
  • Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma.
    Cancer Prev Res (Phila) Volume: 2 Page(s): 823 - 829
    09/01/2009 Authors: Saba NF; Choi M; Muller S; Shin HJC; Tighiouart M; Papadimitrakopoulou VA; El-Naggar AK; Khuri FR; Chen ZG; Shin DM
  • A phase I study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer
    JOURNAL OF THORACIC ONCOLOGY Volume: 4 Page(s): S594 - S595
    09/01/2009 Authors: Owonikoko TK; Ramalingam SS; Harvey D; Saba NF; Kauh J; Shin DM; Sun S-Y; Browning K; Tighiouart M; Khuri FR
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study
    Volume: 27
    05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
  • Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study.
    J Clin Oncol Volume: 27 Page(s): 8060
    05/20/2009 Authors: Khuri FR; Harvey RD; Saba NF; Owonikoko TK; Kauh J; Shin DM; Sun SY; Browning KM; Tighiouart M; Ramalingam SS
  • Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents.
    Curr Opin Oncol Volume: 21 Page(s): 232 - 237
    05/01/2009 Authors: Saba NF; Khuri FR
  • Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.
    Head Neck Volume: 31 Page(s): 475 - 481
    04/01/2009 Authors: Saba NF; Wang X; Mller S; Tighiouart M; Cho K; Nie S; Chen Z; Shin DM
  • Percutaneous feeding tubes in patients with head and neck cancer: rethinking prophylactic placement for patients undergoing chemoradiation.
    Am J Otolaryngol Volume: 30 Page(s): 244 - 249
    01/01/2009 Authors: Lawson JD; Gaultney J; Saba N; Grist W; Davis L; Johnstone PAS
  • Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
    Cancer Volume: 113 Page(s): 97 - 107
    07/01/2008 Authors: Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen ZG
  • A phase II study of oxaliplatin, docetaxel, and capecitabine in advanced carcinoma of the esophagus and stomach
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Anderson EJ; Safran H; Miner T; Shipley J; Mcnulty B; Akerman P; Saba N; Jean M; Millis R; Sio T
  • Defining the interaction of docetaxel and lonafarnib in patients with advanced malignancies
    Volume: 68
    05/01/2008 Authors: Kauh J; Fanucchi M; Escuin D; Saba N; Shin D; Gal A; Kutner M; Harvey D; Giannakakou P; Khuri F
  • Targeting angiogenesis in head and neck cancer.
    Curr Cancer Drug Targets Volume: 7 Page(s): 643 - 649
    11/01/2007 Authors: Saba NF; Shin DM; Khuri FR
  • Targeted therapies in small-cell lung cancer.
    Expert Opin Ther Targets Volume: 11 Page(s): 1033 - 1041
    08/01/2007 Authors: Fernainy K; Saba N
  • Concurrent platinum-based chemotherapy with intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): A retrospective single institution analysis
    Volume: 25
    06/20/2007 Authors: Saba NF; Gaultney J; Edelman S; Tighiouart M; Davis LW; Khuri FR; Chen A; Grist W; Shin DM
  • Rosai-Dorfman disease of the epiglottis.
    J Clin Oncol Volume: 25 Page(s): 2324 - 2326
    06/01/2007 Authors: Talebi T; Johns MM; Sequeira J; Saba N
  • Moving toward bioadjuvant approaches to head and neck cancer prevention.
    Volume: 69 Page(s): S132 - S135
    01/01/2007 Authors: Saba NF; Hammond A; Shin DM; Khuri FR
  • A phase I/II study of oxaliplatin, docetaxel, and capecitabine in advanced carcinoma of the esophagus and stomach.
    J Clin Oncol Volume: 24 Page(s): 14046
    06/20/2006 Authors: Evans DL; Miner T; Ng T; Akerman P; Harrington D; Martel D; Maia C; Benton D; Saba N; Safran H
  • Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Oncology (Williston Park) Volume: 20 Page(s): 153 - 161
    02/01/2006 Authors: Saba NF; Khuri FR; Shin DM
  • Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda.
    Curr Opin Mol Ther Volume: 7 Page(s): 502 - 510
    10/01/2005 Authors: Vulfovich M; Saba N
  • Chemoprevention strategies for patients with lung cancer in the context of screening.
    Clin Lung Cancer Volume: 7 Page(s): 92 - 99
    09/01/2005 Authors: Saba NF; Khuri FR
  • Retinoids as chemoprevention for head and neck cancer: where do we go from here?
    Crit Rev Oncol Hematol Volume: 55 Page(s): 143 - 152
    08/01/2005 Authors: Smith W; Saba N
  • The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
    Oncology Volume: 68 Page(s): 10 - 17
    01/01/2005 Authors: Saba N; Khuri F
  • The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.
    Oncology Volume: 68 Page(s): 18 - 22
    01/01/2005 Authors: Saba N; Khuri F
  • Induction chemotherapy for resectable non-small-cell lung cancer - The Patel/Blum/Argiris article reviewed
    ONCOLOGY-NEW YORK Volume: 18 Page(s): 1606 - +
    11/01/2004 Authors: Saba NF; Khuri FR
  • Molecular biological design of novel antineoplastic therapies.
    Expert Opin Investig Drugs Volume: 13 Page(s): 577 - 607
    06/01/2004 Authors: Vulfovich M; Saba N
  • Novel targeted agents in the treatment of lung cancer.
    Expert Opin Investig Drugs Volume: 13 Page(s): 609 - 629
    06/01/2004 Authors: Saba N; Khuri F
  • Intra-cranial lesions in a patient with Hodgkin lymphoma.
    Leuk Lymphoma Volume: 45 Page(s): 419 - 422
    02/01/2004 Authors: Shet AS; Saba N; Rausch D; Belzer M
  • Chemoprevention in lung cancer.
    Curr Probl Cancer Volume: 28 Page(s): 287 - 306
    01/01/2004 Authors: Saba N; Jain S; Khuri F
  • Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.
    Blood Volume: 102 Page(s): 2678 - 2683
    10/01/2003 Authors: Shet AS; Aras O; Gupta K; Hass MJ; Rausch DJ; Saba N; Koopmeiners L; Key NS; Hebbel RP
  • A 39-bp deletion polymorphism in PTEN in African American individuals: implications for molecular diagnostic testing.
    J Mol Diagn Volume: 4 Page(s): 114 - 117
    05/01/2002 Authors: Zhou X-P; Hampel H; Roggenbuck J; Saba N; Prior TW; Eng C
  • Bone marrow transplantation for nonmalignant diseases.
    J Hematother Stem Cell Res Volume: 11 Page(s): 377 - 387
    04/01/2002 Authors: Saba N; Flaig T
  • Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature.
    Haematologia (Budap) Volume: 32 Page(s): 17 - 23
    01/01/2002 Authors: Saba NF; Warth JA; Ross DG
  • Overview of autologous stem cell transplantation.
    Crit Rev Oncol Hematol Volume: 36 Page(s): 27 - 48
    10/01/2000 Authors: Saba N; Abraham R; Keating A
  • High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.
    Bone Marrow Transplant Volume: 24 Page(s): 853 - 855
    10/01/1999 Authors: Saba N; Sutton D; Ross H; Siu S; Crump R; Keating A; Stewart A
  • High treatment related mortality in cardiac amyloid patients supports the use of less intensive, non cardiotoxic PBSC collection and induction regimens.
    BLOOD Volume: 92 Page(s): 660A - 661A
    11/15/1998 Authors: Saba N; Tsang R; Sutton DM; Meharchand J; Pintilie M; Shepherd F; Keating A; Crump M; Stewart AK
  • Anti-D in a D-positive renal transplant patient.
    Transfusion Volume: 37 Page(s): 321 - 324
    03/01/1997 Authors: Saba NF; Sweeney JD; Penn LC; Lawton JC; Yankee RL; Huang CH; Schanfield MS
  • Metastatic signet-ring cell adenocarcinoma to the urinary bladder.
    Acta Oncol Volume: 36 Page(s): 219 - 220
    01/01/1997 Authors: Saba NF; Hoenig DM; Cohen SI
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements